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STELLWGEN 
1. Verandering van huisvestingscondities kan de timing van de pre-ovulatiore 
Luteiniserend Hormoon (LH) piek bij het varken bdnvloeden. (Dit proefschxift) 
2. Endogene Opioiide Peptiden (EOP) zijn betrokken bij de regulatie van de timing van 
de pre-ovulatoire LH piek. (Dit proefschrift) 
3. Bij studies met naltrexon dient men er rekening mee te houden dat de gevoeligheid 
van varkens voor deze opiaat-receptor antagonist een aanzienlijk individuele variatie 
vertoont. (Dit proefschrift) 
4. Bij het plaatsen van een intracerebroventriculaire canule in dieren die een 
voorhoofdsholte ontwikkelen kan men zich het beste orienteren op het neurocranium 
in plaats van op de externe schedelbeenderen. (Dit proefschrift) 
5. Met transrectale echografie kan naast het moment van ovulatie (Soede et al, 1992) 
ook de folliculaire ontwikkeling nauwkeurig worden bepaald, waarmee deze methode 
een belangrijke bijdrage kan leveren aan onderzoek naar factoren die invloed hebben 
op deze processen bij varkens. (Soede NM, Noordhuizen JPTM, and Kemp B 1992 
The duration of ovulation in pigs, studied by transrectal ultrasonography, is not 
retelated to early embryonic diversity Theriogenology 38 653-666) 
6. The dissociation of peptides with the modified and, more generally, subobtimal 
anchor residue side chains, may explain the presence of empty Major 
Histocompatibility Complex (MHC) class I molecules and free MHC class I heavy 
chains at the cell surface. (Neefjes et al., 1993 European Journal of Immunology 23(4) 
840-845) 
7. Een perfecte beheersing van taal is nog geen garantie voor een goede communicatie 
8. Het eerste axioma van Watzlawick "Men kan met niet be'invloeden", geeft aan dat bij 
proefdierkundig onderzoek het onmogelijk is de proefdieren naief te houden. 
9. Bij de interpretatie van onderzoek is de waarde van "het gemiddelde" weliswaar 
belangrijk doch relatief nietszeggend zonder de waarde van de afzonderlijke 
samenstellende componenten te weten. 
10. Het inkoppen van een voorzet is vaak moeilijker dan op het eerste oog lijkt en hangt 
niet alleen af van de inkopper maar ook van de voorzetter. 
11. Het bezuinigen op onderwijs en gezondheidszorg getuigt van een evengrote 
intelligentie als het afzagen van de tak waar men op zit. In beide gevallen hangt de 
afloop af van de ondergrond waarop men denkt terecht te komen. 
12. Het geven van kleuren aan een kabinet wekt ten onrechte de indruk dat politiek 
kinderspel is. 
13. Men wordt groot door klein te blij ven. 
14. Het begeleiden van studenten is als bakken in Croma : Je moet er even bij blij ven 
door het beste resultaat. 
15. De ironie van het leven: De belangrijkste levenslessen worden gedoceerd door hen die 
zijn overleden. 
16. Met de invoering van het basisonderwijs is de negatieve spiraal van de kwaliteit van 
het totale onderwijsstelsel ingezet. 
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GENERAL INTRODUCTION 
Sexual reproduction is one of the most conserved features during evolution and it is one of 
the most important activities for the survival of animal species. When organisms of a certain 
species don't reproduce, this species will soon be extinct. In general, reproduction appears to 
be as normal and essential as eating and both processes are postponed when survival of the 
organism is threatened e.g. by predators or catastrophes of nature. In reproduction in 
vertebrates it usually takes two to tango, meaning that the eventual production of offspring is 
the result of a complicated interplay between two organisms of different sexes. Since in the 
present thesis attention will be focused on neuro-endocrine processes in reproduction in the 
female gender, this introduction will be restricted to this side of the interplay. 
The Reproductive Axis 
The ability to reproduce depends on the presence of the organs that constitute the 
reproductive axis or hypothalamo-pituitary-gonadal (HPG) axis. The neurones containing the 
decapeptide gonadotropin releasing hormone (GnRH), also known as luteinizing hormone 
releasing hormone (LHRH), are dispersed throughout the ventral forebrain with a majority 
located in the medial preoptic area (MPOA) and mediobasal hypothalamus (MBH) in a 
variety of species (Halasz et ai, 1989; Kraeling and Barb, 1990; Levine et ai, 1991; 
Herbison et ai, 1993; Jarry et al, 1995). Most of these neurones project to the median 
eminence (ME), where GnRH is secreted directly in the pituitary portal circulation (Lehman 
and Karsch, 1993). Subsequently, GnRH selectively stimulates the gonadotrophic cells in the 
anterior pituitary gland to secrete and synthesise the gonadotropins luteinizing hormone (LH) 
and follicle stimulating hormone (FSH)(Clayton and Catt, 1981). Both FSH and LH are 
glycoproteins, that share the same a unit but have a different 13 subunit accounting for the 
biologic difference in hormonal action (Franz, 1988). These gonadotropins affect the gonads 
by promoting cell proliferation, synthesis and secretion of gonadal steroids (oestrogens, 
progesterone and testosterone), gametogenesis and eventually trigger ovulation. The gonadal 
steroids, in turn, exert a feedback at the level of the pituitary and hypothalamus, direct or 
indirect on the gonadotrophic cells and GnRH neurones respectively (Figure 1). 
Oestrus cycle 
The hormonal profiles show periodic changes that are repeated over and over again during 
reproductive life. These menstrual (in humans and non-human primates) or oestrous cycles 
(other mammals), refer to the shedding of uterine endometrium and the accompanying 
bleeding or to the cyclic occurrence of increased activity (oestrum is Greek for "gadfly") 
shown by the female during the period of increased receptivity to the sexual advances of the 
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male (Fink, 1988). These reproductive cycles can be devided in a luteal and follicular phase 
(Figure 2). Roughly, the phase of the cycle from ovulation of the oocyte(s) until menstrual 
bleeding or breakdown of the corpus luteum (remainder of ovarian follicle(s)) is termed the 
luteal or secretory phase. The phase from cessation of menstrual bleeding or breakdown of 
corpus luteum ending with the ovulation of the matured oocyte(s), is termed the follicular or 
proliferative phase (Franz, 1988). 
External 
influences 
| _ P ; **":•;>& LH/FSH 
Figure 1: Schematic representation of the reproductive axis in the female. GnRH(f) is secreted from the 
hypothalamus into the portal blood vessels and stimulates the secretion of the gonadotropic hormones (LH and FSH; 
*) from the pituitary. LHand FSHincrease synthesis and secretion of ovarian steroids (E2J1 and P), which, together 
with several internal and external influences, exert a direct or indirect "positive" and negative feedback on the 
secretion of GnRH, GnRH-receptors ( h4) and/or gonadotropins. 
Pulsatillty of GnRH and Gonadotropin Release 
It is now well established that GnRH is released in rhythmic secretory bursts and that this 
pulsatile pattern of secretion functions as the primary neuro-endocrine determinant of 
pituitary pulsatile LH secretion (Yen et al, 1972; Carmel et al, 1976; Levine et al, 1982). 
Temporal association between GnRH and gonadotropin pulses has been confirmed in a 
variety of species (Levine et al, 1985; Pau et al, 1986; Karsch et al, 1987; Urbanski et al, 
1988), though less compelling for FSH than for LH. The physiological mechanism of the 
pulsatile pattern of gonadotropin secretion was discovered by Yen et al. and his group (1972). 
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They have reported data indicating that the pulsatile release of endogenous GnRH must be a 
consequence of a synchronous discharge of GnRH containing neurones effected by some 
neural signal generator or oscillator, referred to as the "GnRH pulse generator" (Yen et al, 
1972). Furthermore, the physiological importance of the pulsatile GnRH secretion has been 
shown by several groups (Yen et al, 1972; Santoro et al, 1988; Levine et al, 1991; 
Rossmanith, 1991; Kotsuji et al, 1992). They have reported that qualitative and quantitative 
differences in the pulsatile pattern, as observed between different phases of the cycle and 
between subjects with and without ovarian function, are essential for an accurate regulation of 
all kinds of events determining female fertility. For example, the number of GnRH receptors 
on and the LH secretion from pituitary gonadotropic cells are decreased after continuous 
infusion of GnRH, but increased after intermittent administration of GnRH (Pickering and 
Fink, 1976; De Koning et al, 1978). Thus, pulsatile secretion of GnRH can lead to a "self-
priming" effect of GnRH, which appears to be necessary for induction of the preovulatory LH 
surge. 
The pulsatile pattern of GnRH and LH secretion, reflected by frequency and amplitude of 
pulses, changes during the oestrous and the menstrual cycle. During the luteal phase, pulses are 
of low frequency and high amplitude. This pattern changes to one of high frequency and low 
amplitude pulses at the start of the follicular phase. At the end of the follicular phase, pulses of 
high frequency and high amplitude preceed and constitute the preovulatory LH surge, that induces 
ovulation (Genazzani et al., 1992). These dynamics of LH secretion are mainly determined by the 
hypothalamic GnRH pulse generator (Knobil, 1990; Veldhuis, 1990). However, there is some 
evidence that the pituitary LH response to GnRH changes during the oestrous and the menstrual 
cycle (Apfelbaum, 1981; Rossmanith, 1991). 
Gonadal Steroids in Regulating Pulsatile GnRH and LH Secretion 
The changes in the pulsatile GnRH and LH secretion during the oestrous cycle are, amongst 
others, regulated by the gonadal steroids progesterone (P) and 1713-oestradiol (E2B) through a 
feedback mechanism. During the luteal phase, P is produced in large amounts by the corpus 
luteum, with very low production of E2I3 and androgens (Franz, 1988). The major effect of P 
is decreasing the LH pulse frequency by decreasing the GnRH pulse frequency (Bouchard et 
al, 1988; Couzinet and Schaison, 1993). The high LH pulse amplitude during the luteal 
phase is thought to be related to the low GnRH pulse frequency at the level of the 
hypothalamus. However, Couzinet and Schaison(1993) speculate that P might also increase 
LH release at the pituitary level. The significance of the very low concentration of E2I3 and 
androgens under these conditions are not understood. The decrease of P from luteal tissue at 
the end of the luteal phase leading to the start of the follicular phase coincided with an 
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Figure 2 Profiles of the concentrations (mean ± SEM) of the pituitary hormones LH, FSH, PRL and the ovarian 
steroids E2fi and P during the follicular and luteal phase of the oestrus cycles of 19 female pigs (modified after 
Helmond, FA., unpublished observations) 
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increase in pituitary FSH secretion which induces the development of ovarian follicles for the 
next cycle and stimulates the biosynthesis of E213 in the steroid-producing cells of the ovarian 
follicles (Franz, 1985; Bouchard et ai, 1988). E2B is reported to have both stimulatory and 
inhibitory actions on the GnRH and gonadotropin secretion, with FSH having a higher 
sensitivity for E2B than LH (Couzinet and Schaison, 1993). In early and mid follicular phase, 
E2B exerts a negative feedback by inhibiting the LH pulse frequency, reducing multi-unit 
activity in the mediobasal hypothalamus, which is thought to be part of the "GnRH pulse 
generator" (Kesner et ai, 1987; Tanaka et ai, 1992; O' Byrne et ai, 1993). However, other 
studies also suggest a pituitary site of action for the negative feedback of oestradiol by 
blocking LH and FSH secretion (March et ai, 1981; Knobil and Hotchkiss, 1988). 
During late follicular phase, E2B switches to a "positive feedback" which is mainly exerted at 
the level of the pituitary as demonstrated by Knobil and Hotchkiss (1988) in ovariectomized 
monkeys with hypothalamic lesions. In vitro studies of rat pituitary cells in culture 
demonstrate an increase in the response of the pituitary to GnRH administration following 
administration of E2B (Drouin et al., 1976; Kamel and Krey, 1982). Furthermore, the number 
of GnRH receptors on gonadotropic cells, and transcription and storage of gonadotrophin 
subunits is increased by E2B (March et al., 1981; Bouchard et al., 1988). 
The follicular phase ends with the preovulatory LH surge, which occurs within hours after 
peak levels of E2B have been reached. Studies in a variety of species have shown that a 
preovulatory LH surge can be triggered if plasma levels of E26 are maintained high enough 
for a certain amount of time (dependent on the species) and as long as GnRH is present 
(Knobil et al., 1980; Fink, 1988; Karsch et al., 1992). Other studies have demonstrated that 
plasma P and 170H-P start to increase 12 h before a detectable rise in LH in women, and 6-
12 h before a mid-cycle rise in LH in monkeys, which might suggest that progesterone is 
required to establish a preovulatory surge to its full magnitude (Bouchard et al., 1988; 
Mahesh et al., 1996). Such a synergy between the "positive feedback" of P and E2B has also 
been described in vitro (Karsch, 1987). 
The mechanism by which gonadal steroids exert their feedback on the level of the 
hypothalamus is still subject of many studies. Both P and E2B do not seem to affect the 
GnRH secretion by directly inhibiting the GnRH neurones in the hypothalamic nuclei, since 
these GnRH neurones do not posses receptors for P and E2B (Shivers et al., 1983; Herbison 
and Theodosis, 1992). Although, recently functional receptors for E2B have been found in 
immortalised mouse GnRH neurones (GT1-7 cells; Shen et ai, 1998), it is likely that gonadal 
steroid signals are relayed to GnRH cells by other neurones. Indeed, steroid receptors have 
been found on a variety of neurones, ranging from gamma amino-butyric acid (GABA; 
Fliigge et ai, 1986) and neurotensin neurones (Axelson et ai, 1992; Herbison and Theodosis, 
1992) in the preoptic area, to neuropeptide Y and B-endorphin containing neurones in the 
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arcuate and periarcuate region (Sar et al, 1990; Lloyd et al, 1991; Leshin et al, 1992), the 
norepinephrin-containing systems originating in the brainstem (Heritage et al, 1977; Zhen 
and Gallo, 1995) and the tubero-infundibular dopaminergic neurones (Merchenthaler et al, 
1995). In addition, changes in norepinephrine, dopamine and 13-endorphin secretion have 
been shown to be related to stage of the oestrous cycle (Di Paolo et al, 1988; Levesque et al, 
1989; Lloyd et al, 1991, ThyagaRajan et al, 1995). In particular 13-endorphin, an 
endogenous opioid peptide, is of interest because besides its direct inhibitory action on GnRH 
secreting cells in the periarcuate region (Blank et al, 1985; Horton et al, 1987; Rodriguez 
and Wise, 1989), it may inhibit GnRH secretion through direct actions on norepinephrenic 
neurones in the preoptic area (Mallory et al, 1989; Chang et al, 1993). 
Endogenous Opioid Peptides 
Endogenous opioid peptides (EOP) have long been implicated in the control of female 
reproduction, based on the clinical observation of profound disturbances in the menstrual 
regularity of morphine addicted women. Since Hughes et al. (1975) first described 
endogenous peptides with opiate-like actions, numerous investigations have provided 
evidence for the pivotal role of EOP's in the neuro-endocrine control of gonadotropin 
secretion in a variety of animals (Barb et al, 1985; Nanda et al, 1991; Currie et al, 1992; 
Aurich et al, 1995) and humans (Genazzani et al, 1993). Before going into the role of EOP's 
in the regulation of LH and GnRH secretion, the nature and origin of these peptides will be 
described. 
As yet, three major groups of opioid peptides have been identified (Lord et al, 1977; 
Guillemin, 1980; Akil et al, 1984; Yen, 1991): the endorphins (B-endorphin and related 
peptides), the enkephalins (met- and leu-enkephalin and related peptides) and the dynorphins 
(dynorphin A and B and related peptides). B-Endorphin as a 31-amino acid sequence derived 
from the proopiomelanocortin (POMC) precursor (Eipper and Mains, 1980) is considered the 
most important opioid peptide for the neuro-endocrine regulation of reproduction 
(Rossmanith, 1992). The pentapeptides Met- and Leu-enkephalin, originate from 
proenkephalin A (Lazarus et al, 1976; Lowry et al, 1980; Akil et al, 1984), and the 
prodynorphin precursor peptide is cleaved into dynorphin A, dynorphin B (also known as 
rimorphin) and a- and B-neo-endorphin (Akil et al, 1984; Rossier, 1988). All three types of 
EOP's are widespread in the brain, mainly localised in hypothalamic areas. In addition, 
enkephalins and B-endorphin are found in the anterior pituitary and other organs. 
Pharmacological investigations have permitted identification of at least five distinguishable 
opioid receptor types: the u-, e-, 5-, K- and o-receptors (Paterson et al, 1983; Akil et al, 
1984; Ferin et al, 1984; Yen et al, 1991). All EOP's share similar peptide sequences, and 
they may therefore be functionally active at more than one of the distinct receptor types 
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(Rossmanith, 1992). In neuroendocrine processes, opioids thus may operate as 
neurotransmitters or neuromodulators. Since EOP's are locally secreted within the anterior 
pituitary, they may also exert paracrine effects locally (Barkin et al, 1983; Rossmanith, 
1992). 
High densities of opioid receptors are found in a wide variety of nuclei throughout the brain 
(Pfeiffer et al, 1982), and EOP's play a role in the regulation of various vegetative and 
behavioural functions and the neuroendocrine control of hormone release. Opioids have been 
implicated in functions such as pain, temperature perception, hunger and thirst control, sexual 
behaviour and adaptation to different environmental inputs (Guillemin, 1980; Akil et al, 
1984; Grossman, 1988; Rossmanith and Lauritzen, 1991; Armeanu, 1991). In addition, it has 
been observed that endorphins are activated during the response to stress (Akil et al, 1984; 
Bloom, 1980; Grossman et al, 1982; Rivier and Rivest, 1991; Dobson and Smith, 1995), 
defined by Selye (1973) as "a non-specific response of the body to any demand (usually 
noxious) or to any stimulus causing an alteration in homeostatic processes". For example, in 
pigs, it has been shown that tethered housing -a chronic stressor- increases adrenocortical 
sensitivity to ACTH, its steroidogenic capacity and plasma concentrations of Cortisol and 
prolactin (PRL; Janssens, 1994; Janssens et al, 1994; Janssens et al, 1995a). Furthermore, 
tethered housing increases endogenous opioid activity (Janssens et al, 1995b) and the number 
of u-opioid receptors in the brain (Zanella et al, 1996). In addition, tethered housing leads to 
opioid dependent stereotyped behaviour (Cronin, 1985; Schouten en Wiepkema, 1991), with 
a negative correlation between both u and K receptor densities and duration of stereotypies 
(Zanella et al, 1996). 
Opioidergic Control of Gonadotropin Release During The Oestrus Cycle 
Numerous studies have shown that the expression of endogenous opioid activity plays a 
pivotal role for gonadal steroids feedback during the oestrous cycle in a variety of species 
(Haynes et al, 1989; Weiland and Wise, 1990; Schwarz and Pohl, 1994; Simpkins, 1994). As 
ovarian steroid concentration changes during the transition from the follicular to the luteal 
phase, opioid tone is subsequently altered (Lloyd et al, 1991, Thorn et al, 1996). During the 
P dominated luteal phase, EOP's exert a tonic inhibition on LH pulse frequency resulting in 
decreased plasma LH concentration as has been shown in rat (Higuchi and Kawakami, 1982), 
sheep (Montgomery et al. 1985), pig (Barb et al, 1988) and humans (Rossmanith et al, 1989). 
Treatment with the opioid receptor antagonist naloxone or naltrexone during the luteal phase, 
increases plasma LH concentration. The involvement of EOP's in regulating pulsatile LH release 
during the E2B dominated follicular phase is not clear. It seems that EOP's are not involved in the 
negative feedback of E2I3 on the pulse amplitude and mean plasma concentration of LH during the 
early follicular phase. However, during the late follicular phase and the presumed positive 
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feedback of E2/3 increases of these parameters of LH release were found after treatment with 
opioid receptor antagonists in humans (Rossmanith et al, 1989), rats (Piva et al, 1985) and pigs 
(Okrasa et al, 1992). Prolonged opioidergic blockade elicits a markedly enhanced LH pulse 
amplitude but not pulse frequency (Rossmanith et al, 1989). In addition, there is increasing 
evidence that EOP's might play a role in the generation and timing of the preovulatory LH surge 
and oestrus (Massotto et al, 1990; Kraeling et al, 1992; Walsh and Clarke, 1996; Smith and 
Gallo, 1997). Armstrong et al. (1988) reported that chronic administration of morphine (sc) to 
sows for 5 days after weaning delayed the onset of oestrus, and other studies (Ziecik et al, 
1994; Kraeling et al, 1992) reported a delayed preovulatory LH surge in E2C primed OVX 
gilts after iv and ICV morphine treatment with no effect on the height of the surge. 
Aims And Outline Of The Thesis 
LH secretion during the oestrous or menstrual cycle, and the luteal phase in particular, has been 
studied in a variety of species as sheep (Whisnant et al, 1991), human (Fillicori et al, 1986, 
Rossmanith et al, 1990), pig (Okrasa and Tilton, 1992) and primate (Norman et al, 1994). During 
the luteal phase, plasma LH concentration has been shown to be decreased by endogenous opioid 
peptides (EOP's), mediating the negative feedback of progesterone (P; Yang et al, 1988, Barb, et 
al, 1992; Kaynard et al, 1992). However, relatively few data are available on the pattern of 
pulsatile LH release during the E2B dominated follicular phase, in particular with regard to pulse 
frequency, pulse amplitude and timing of the preovulatory LH surge, events that participate in, and 
possibly determine, the timing of ovulation and therefore fertility and success of fertilisation. In 
addition, stressful conditions have been shown to have adverse effects on LH secretion 
(Brann and Mahesh, 1991; Dobson and Smith, 1995) and hormones of the hypothalamus-
pituitary-adrenal (HPA)-axis and EOP's released during stress have been shown to inhibit the 
hypothalamus-pituitary-gonadal (HPG) axis. 
The aim of the present thesis was to gain insight in the neuroendocrine regulation of the LH 
secretion during the follicular phase, and in particular to determine whether EOP's also play a role 
in the pulsatile LH release and the timing of events leading to the preovulatory LH surge and 
oestrus. The female pig was used as experimental animal for a number of reasons. In modern 
intensive pig breeding where tethered housing is common practice, a large percentage of the sow 
population shows reduced fertility and has to be replaced. Insight in the mechanisms underlying 
reduced fertility could contribute to effective pig breeding. Furthermore, in pigs, like in primates 
and humans, opioid modulation of the LH secretion is dependent on the gonadal steroid 
environment which is, although predominantly at the hypothalamic level, also regulated at the 
level of the pituitary (Knobil, 1980). Thus the tethered pig would render an excellent animal 
model for studying the effects of chronic stress, and possible increased opioid activity, on LH 
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secretion during the oestrous cycle at the hypothalamic and pituitary level (Cronin, 1985; 
Schouten en Wiepkema, 1991; Janssens, 1994; Zanella et al, 1996). 
Since it is extremely difficult to determine the transition from the luteal into the follicular phase, 
the oestrous cycles of all animals that were studied during the follicular phase, were synchronised 
using the progesterone agonist altrenogest. 
Before studying the possible effects of EOP's during the follicular phase in detail, it was 
investigated whether a change in housing condition, from life long tethered housing to a loose 
housing system in individual pens, affects the LH pulse characteristics during altrenogest 
treatment, the timing of the preovulatory LH surge and the LH secretion during the following 
oestrous cycle (Chapter II). The change in housing condition appeared to advance the 
preovulatory LH surge and to decrease mean plasma LH concentration, which could not be 
explained with differences in activation of the HPA system. The question arose whether these 
effects could be ascribed to a change in the reactivity of the EOP-system, which has been 
shown to occur in tethered housing (Janssens et al, 1995b; Zanella et al, 1996; Loyens, 
Schouten and Wiegant, unplublished observations). To address this question, we decided to 
use the potent and long acting opioid receptor antagonist naltrexone. This drug had not been 
used in pig before, and therefore we first designed a study with the objective to investigate 
the possible individual variability in the response of the reproductive axis by determining the 
increase in mean plasma LH concentration after intravenous administration of saline or 5 
doses of naltrexone (Chapter III). 
Subsequently, we determined the pulsatile pattern of LH release, and the possible role of EOP's in 
modulating this pattern, during 4 days of the follicular phase in Chapter IV. Furthermore, the 
effect of EOP's on the occurrence of the first day of oestrus was investigated. The results from this 
experiment suggested that EOP's do not inhibit the pulsatile LH secretion as such, but might affect 
the events leading to the timing of oestrus and possibly the preovulatory LH surge. 
A pilot study, described in Chapter V, was designed to investigate changes in the responsivity 
of the pituitary gonadotrophs in vitro to GnRH changes during the follicular phase. In 
addition, the possible role of EOP's therein was studied. 
A novel intracerebroventricular (ICV) cannulation technique for pigs was developed (Chapter 
VI). This technique, was used to treat freely moving intact gilts (nulliparous pigs) with repeated 
ICV injections of naltrexone on multiple days during the follicular phase of the oestrous cycle 
(Chapter VII) to determine whether the shift of oestrus (as found in Chapter IV) or the 
preovulatory LH surge (as found in Chapter II) was a consequence of changing opioid 
activity in the brain. 
In Chapter VIII, the results of the present thesis are summarised and discussed. 
Chapter II 
Change in housing conditions alters the timing of the 
preovulatory LH surge in sows 
Dierx, J.A.J. , Kemp, B. , Soede, N.M. , Helmond, F.A. , van der Heide, D. and 
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Abstract 
The effect of housing conditions on the pulsatile LH secretion during the oestrous cycle were 
investigated in stress-adapted sows. Multiparous sows with a history of long term tethered 
housing either remained tethered housed (N=10; TETHER pigs) or were individually loose 
housed (N=12; LOOSE pigs). The oestrous cycles of the pigs were synchronized by 
altrenogest treatment during 21 days (first day following treatment: Day 0). Blood samples 
for hormone determinations were collected with 12 minutes intervals on Days -3, 2, 4 and 19, 
and every 4 hours from Day 4 until the preovulatory LH surge had occurred. 
During Day -3, Day 19 (luteal phase), mean plasma LHwas lower in LOOSE than in 
TETHER animals, but LH pulse frequency and amplitude were not different between housing 
conditions. The preovulatory LH surge and oestrus occurred later in LOOSE than in 
TETHER animals (116 ± 5 vs 91 ± 3 h, respectively 6.7±0.4 vs 5.3 ±0.2 days after 
terminating altrenogest treatment). LH surge height and duration of oestrus were not 
different between housing conditions. During the follicular phase, the LH pulse frequency was 
lower, and pulse amplitude and mean plasma LH were higher on Day 2 than on Day 4. 
Housing condition had no effect on these parameters. 
The present data suggest that a change in housing condition affects LH secretion in pigs with 
a history of tethered housing. Conversely, this suggests that chronic stress leads to alterations 
in the mechanisms regulating LH secretion. 
Introduction 
Reproductive processes, like LH secretion, follicle development and ovulatory activity, are 
influenced by stressful conditions (Dobson and Smith, 1988; Brann and Mahesh, 1991). As 
reviewed by Brann and Mahesh (1991), the effects of stress on the reproductive axis seem to 
depend on whether the stressor is acute or chronic. Acute stress can stimulate LH release and 
enhance ovulatory activity (Higuchi et al, 1986; Armario et al, 1987; Briski and Sylvester, 
1988), whereas chronic stress can inhibit LH secretion, cyclicity and follicle development 
(Gray et al, 1978; Tache et al, 1978; Rasmussen and Malven, 1983; Moberg, 1987). It is 
thought that the effects of stress on reproductive processes are brought about by altered 
activity of mediators of the stress response. Indeed, hormones of the hypothalamus-pituitary-
adrenal (HPA)-axis and endogenous opioid peptides (EOP's) can inhibit the hypothalamus-
pituitary-gonadal (HPG)-axis (Naylor et al, 1990; Norman et al, 1994; Akema et al, 1995). 
In pigs, it has been shown that long term tethered housing induces symptoms typical of 
chronic stress that are generally thought to relate to adverse effects on physiological 
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functions, welfare and health of the animals. Thus, tethered housed pigs show increased 
adrenocortical steroidogenic capacity and sensitivity to adrenocorticotropin (ACTH), elevated 
plasma Cortisol and prolactin concentrations and a flattened diurnal rhythm of Cortisol 
(Janssens et al., 1994, 1995a). Interestingly, there is evidence for stress-adaptive changes in 
long-term tethered housed pigs. These include an increase in the endogenous opioid activity 
that mitigates hormonal and autonomic responses to acute challenges (Janssens et al., 1995b, 
Zanella et al., 1996; Loyens, Schouten and Wiegant unpublished observations). Increased 
activity of endogenous opioids also underlies the behavioural stereotypies that are frequently 
observed in tethered pigs, particularly when the animals are aroused and that are associated 
with de-arousal and diminished autonomic and pituitary-adrenocortical responsivity (Cronin, 
1985; Schouten en Wiepkema, 1991). Adaptive changes in regulation of behaviour and 
physiology become most evident under conditions of environmental demand. In commercial 
breeding farms, tethered housing is frequent practice, but there is no evidence sofar for 
impaired reproductive performance of the animals, suggesting that adaptive mechanisms 
counteract the detrimental effects of stress on reproductive regulation. 
The present study is designed to investigate whether chronic tethered housing of sows affects 
the LH pulse characteristics during the oestrous cycle and the timing of the preovulatory LH 
surge after oestrus synchronisation with the progesterone analogue altrenogest. 
Materials and methods 
Animals and housing 
Twenty six commercial, muciparous (parity 2-7), crossbred sows (Fl, Great Yorkshire x 
Dutch Landrace) were obtained from a Dutch breeding company and had a history of long 
term tethered housing. On arrival, they were randomly assigned to tethered housing with a 
neckchain, or loose housing in individual pens of 6 m2 with a concrete floor covered with 
woodshavings, except for a slatted dunging area at the rear of the pen. Lights were on from 
7.30 h to 19.30 h and ambient room temperature ranged from 15 °C to 25 °C. At 800 hours 
and 1600 hours the animals were fed 1.25 kg of dry sow feed (12.2 MJ of metabolizable 
energy per kilogram containing 15.4% crude protein) by hand. Water was available ad 
libitum through a nipple drinker. 
Surgery 
In order to collect frequent bloodsamples, the sows were surgically fitted with a permanent 
jugular vein catheter (Silastic® medical grade tubing, 0.040 in. id., 0.085 in. o.d.; Dow 
Corning, Michigan U.S.A.) under sterile conditions and under general anaesthesia with 
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inhalation of 02/N20, enflurane Ethrane®, Abott B.V., The Netherlands) as described 
previously (Janssens et al, 1994). The animals were equipped with a harness to protect the 
cannula, which was externalized between the scapulae. The harness (23 cm x 20cm; polyvinyl 
chloride with nylon; Bizon Chemie, The Netherlands) was fixed at the back of the animals 
with a belt around the chest during the week before surgery in order to habituate to the 
harness. All animals were treated with antibiotics (12 ml of T.S. Sol®, containing 
trimethorprim and sulfamethoxazol, orally; Dopharma, The Netherlands) once daily from 3 
days prior to 3 days after surgery. To prevent obstruction by bloodclots, the catheters were 
flushed with saline once weekly and filled with heparinized saline (25 IU heparin/ml of 0.9% 
saline; Leo Pharmaceutical Products, The Netherlands) when not in use. When catheter 
patency was reduced, obstructions were removed as described by Leuvenink and Dierx 
(1997). In short, the catheter was filled with a solution of 25000 IU kabikinase (Kabi 
Pharmacia, Sweden), 2500 IU heparin and 0.2 ml Ticarpen® (Beecham, England) to 25 ml 
sterile 25% polyvinylpyrrolidone/saline (Merck, Germany), and after 1 week, flushed with a 
2% heparine/saline solution. 
Experimental design 
On arrival at the facilities of the Wageningen Agricultural University, 13 animals were 
housed tethered (TETHER) with a neck chain and 13 animals were housed loose (LOOSE) in 
individual pens. After 1 week, surgery was performed and the animals were allowed 
approximately 1 week for recovery during which they were frequently handled and habituated 
to the bloodsampling procedure. Then, the oestrous cycles of all animals were synchronized 
by daily oral administration of 20 mg of the progesterone agonist altrenogest (Regumate^ for 
21 days (day 0). The day of altrenogest withdrawal was designated Day 0. On Day -3 (the 
19th day of the altrenogest treatment) and at Day 2, 4 (both follicular phase) and 19 (luteal 
phase) after altrenogest withdrawal, frequent bloodsamples were taken (every 12 minutes 
during 12 hours) from 8.30 h until 20.30 h. After Day 4, bloodsamples were taken every 4 
hours until the preovulatory LH surge had occurred as determined by a fast LH 
radioimmunoassay. Of all 22 animals the peak value of preovulatory LH surge was detected. 
Bloodsampling 
Blood samples were taken according to the procedure as described previously (Janssens et al, 
1994). Immediately after collection, the blood samples (approximately 5 ml) were transferred 
to ice-cooled polypropylene tubes containing 50 ul EDTA solution (144 mg EDTA/ml of 
saline; Triplex®III, Merck Nederland BV.The Netherlands). The tubes were shaken, kept on 
ice and subsequently centrifuged at 3000xg for 15 minutes at 4 °C. Plasma was collected and 
stored at -20 °C until hormone analysis. 
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Hormone analysis 
LH. Plasma samples were analysed for LH using a double anti-body radioimmunoassay 
(RIA) as described by Niswender et al. (1970), using porcine LH (pLH iodination grade 
batch 004/3; potency, 0.85 x NIH LH-S19; UCB bioproducts, Brussels, Belgium) as a 
standard and for radioiodination (specific activity, 38 uCi/ug). Anti-porcine LH batch 004 
(UCB bioproducts, Brussels, Belgium) was used at a final dilution of 1:360 000, which gave 
an initial binding of the labeled hormone of approximately 39%. The main cross reacting 
peptides were pFSH (2.7%), pLHa (1.1%), pTSH (0.5%) and pTSHa, pTSHB and pLHB 
(all<0.1%). Sac-Cel was used as the second antibody, (donkey anti-rabbit; Wellcome Reagents, 
Beckenham). The minimal detectable concentration at the 90% B:B0 was 0.1 ng/ml. The 
interassay coefficient of variation was 14.4 % and the intra-assay coefficient of variation was 7.2 
%. The fast LH RIA was performed according to the same method but with slight modifications of 
incubation time and temperature (2 hours at 37 °C). 
Cortisol. Hourly samples on Day -3 and 19, were analysed for Cortisol. After extraction of plasma 
with dichloromethane (DCM, Merck, Darmstadt, Germany), Cortisol concentration was 
determined using a single anti-body radioimmunoassay. For estimation of procedural losses, 500 
cpm of [l,2,6,7-3H]cortisol (TRK407, specific activity 80.5 Ci/mmol, Amersham Int., 
Amersham U.K.) was added to 1 ml plasma sample and mixed with 3 ml DCM. The organic 
phase of the mixture was evaporated under a stream of nitrogen and redissolved in 500 jtl 
phosphate buffer with 1% BSA. An aliquot of 150 n\ was taken to determine the recovery of 
[ HJcortisol. Cortisol concentrations were measured in duplicate (2 aliquots of 50 fil) using a 
single-antibody radioimmunoassay (RIA) technique, previously described by Janssens et al. 
(1994). The main crossreacting steroids were 21-desoxycortisol (72%), cortisone (59%), 
prednisolone (53%), 11 desoxycortisol (43%), corticosterone (10%), progesterone (2.3%), 
estradiol-176, dexamethasone, and triamcinolone acetonide (all <0.1%). The sensitivity of the 
assay was 0.5 ng.ml"1 at the 90% B/B0 level. The intra- and inter-assay coefficients of variation 
were 8.2 % and 14.7 % respectively. The amount of Cortisol was expressed in ng.ml"1 after 
correction for procedural losses. 
Detection of oestrus 
Oestrus detection was performed by a back-pressure test in the presence of a vasectomized 
boar once daily in the morning on all days until 1 month after withdrawal of altrenogest 
treatment. The time of oestrus was defined as the first day the sow showed a standing 
response. When animals had not shown oestrus before day 7, ultrasound was performed as 
described by Soede et al. (1991) to determine whether ovulation had occurred. 
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LH Pulse detection 
The profiles of the pulsatile LH release were analysed using the pulse analysis program of 
Maxima/Chromcard (Fisons Instruments,Interscience, Breda, Holland) with baseline calculated 
according to an allgorithm taking into account the total LH profile. A pulse was defined by a 
baseline-peak ratio of 0.5 or higher and a minimal area under the pulse of 6.0 x 10 ng.ml" min. 
Data analysis and statistics 
Data of pulse frequency, pulse amplitude and mean plasma LH concentration of LH during 
and after altrenogest withdrawal, time and height of the preovulatory LH surge and the first 
day of oestrous, obtained after altrenogest withdrawal, were analysed using SAS statistical 
analysis system (1990). In addition, to determine whether effects found in pulse frequency, 
pulse amplitude and mean plasma LH were due to differences in the timing of the 
preovulatory LH surge, data were analysed relative to the day of preovulatory LH surge. By 
synchronising the data, the number of animals per housing condition is reduced. On Day -2 
and -3, most animals had data on pulse frequency, pulse amplitude and mean plasma LH, and 
were used to analyse possible effects of housing conditions on pulsatile LH release relative to 
the preovulatory LH surge. The effect of tethering on these parameters, and on hourly 
samples of Cortisol and on the daily mean plasma level of Cortisol on Day -3 and Day 19, was 
tested using the GLM procedure using the model: Y{j =u + T i + e ^ Dj +(TXD);J H-e ;^ Where 
Yjj = value of parameter in a sow (n=22) receiving treatment i on sampling day j ; u = overall 
mean; T;= fixed effect of treatment i (1,2); e ^ error term 1, which represents the random 
effect of sow within treatment i; Dj= fixed effect of sampling day j (1,..,4); e2ij= error term 2, 
which represents the random effect of treatment i between sampling days j . The effect of 
tethering treatment was tested against error term 1. The other effects were tested against error 
term 2. Differences were considered significant when P<0.05. Pulse amplitude and mean 
plasma LH did not have a normal distribution and were therefore subjected to non-parametric 
analysis using the Kruskal-Wallis test from the NPAR1WAY procedure of the SAS 
programme. 
Results 
General 
Of the 13 TETHER and 13 LOOSE sows, 3 TETHER animals and 1 LOOSE animal did not 
show oestrous behaviour after altrenogest treatment was terminated. Ultrasound with the sows 
that did not show oestrous behaviour showed that 1 TETHER and 1 LOOSE animal had 
developed cystic ovaries. The other 2 TETHER sows had corpora lutea and were therefore 
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classified as having displayed silent oestrus. Data of all 4 animals were excluded from 
statistical analysis and, as a consequence, 12 LOOSE and 10 TETHER sows were used to 
assess LH pulse characteristics. 
Plasma LH and Cortisol concentration during the luteal phase with and without altrenogest 
No differences were found in number of LH pulses (p=0.50) and LH pulse amplitude 
(p=0.61) between endogenous (Day 19) and exogenous (altrenogest period; Day -3) 
progesterone dominance (Table 1), or between LOOSE and TETHER sows (p=0.40 and 
p=0.83 respectively). Furthermore, no interaction between housing conditions and altrenogest 
treatment was found (p=0.60 and p=0.50 respectively). 
Mean plasma LH was not different between Day -3 and Day 19 (p=0.57). However, a 
significantly higher mean plasma LH was found in TETHER than in LOOSE animals 
(p=0.005), with no interaction between housing condition and altrenogest treatment (p=0.80). 
In plasma Cortisol, no differences were found (p=0.24) between LOOSE and TETHER sows, 
nor between Day -3 and Day 19 (p=0.09). Furthermore, no significant interaction between 
housing and day was found(p=0.99). In addition, there was no indication for the presence of a 
diurnal rhythm in Cortisol in of both LOOSE and TETHER sows. The daily mean plasma 
concentration of Cortisol of LOOSE respectively TETHER animals on these days was: 15.2 ± 
2.0 ng/ml versus 20.2 ± 2.6 ng/ml (mean ± SEM; n=12 versus n=10) on Day -3 and 25.1 ± 
6.5 ng/ml versus 29.1 ±5.0 ng/ml (mean ± SEM; n=12 versus n=9) Day 19. 
Table 1: Pulsatile LH release during progesterone dominance in the luteal phase and under 
altrenogest treatment in LOOSE and TETHER sows. 
Day-3 Day 19 
LOOSE TETHER LOOSE TETHER 
(n=12) (n=10) (n=12) (n=9) 
number of pulses (#/12h) 6.08 ±0.41 6.10 ±0.61 6.17 ±0.53 6.78 ±0.74 
pulse amplitude (ng. ml"1) 8.54±1.60 14.1 ±5.60 10.5 ±1.78 12.6±4.13 
mean plasma LH (ng.ml1) 9.44 ±2.05 15.9 ±2.68* 7.55 ±0.74 15.4 ±3.76* 
Data of animals during altrenogest treatment (Day -3) and the luteal phase of the oestrous cycle (Day 19) are 
presented as means ± SEM. 
* = significantly different from loose housed (p<0.05). 
Oestrus 
LOOSE sows came in oestrus on average at 6.7 ± 0.4 days after termination of altrenogest 
treatment, which was significantly (p=0.002) later than TETHER sows that came in oestrus 
after on average at 5.3 ± 0.2 days. The duration of oestrus was not different (p=0.47) in 
LOOSE compared to TETHER sows (2.2 ± 0.2 days and 2.2 ± 0.4 days respectively). 
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Preovulatory LH surge 
The peak value of the preovulatory LH surge in the TETHER animals (n=10) occurred on 
average at 91 ± 3 (mean ± SEM) hours after altrenogest withdrawal (see Figure 1). This is 
significantly (p=0.001) earlier than in the LOOSE animals (n=12), in which the preovulatory 
LH surge peaked at 116 ± 5 hours after altrenogest withdrawal. There was no significant 
difference in the height of the preovulatory LH surge between LOOSE and TETHER sows 
(36.7 ± 5.3 ng/ml versus 49.5 ± 6.3 ng/ml; mean ± SEM; p=0.16). 
Day of Preovulatory LH Surge 
loose (n=12) 1 I tethered (n=10) 
s 
o 
day after altrenogest withdrawal 
Figure 1: Time of the preovulatory LH surge (days after altrenogest withdrawal) in LOOSE and TETHER 
sows. Distribution of number of LOOSE (closed bars, total n=l2) and TETHER (open bars: total n=I0) 
animals, that have their preovulatory LH surge, over the period after altrenogest withdrawal. 
Pulsatile LH release on Day 2 and 4 after altrenogest withdrawal 
In pulse frequency a significant day effect (p=0.007; Table 2) was found. Pulse frequency on 
Day 2 after altrenogest withdrawal was significantly higher compared to Day 4. No housing 
effect (p=0.40) was found, and no significant interaction between housing and day was found 
in pulse frequency (p=0.39). 
A significant day effect (p=0.01) was found for LH pulse amplitude, with the amplitude on 
Day 4 being significantly higher than on Day 2 (table 2). Yet, no differences in pulse 
amplitude were found between LOOSE and TETHER housing (p=0.35), and there was no 
significant interaction between housing and day in pulse amplitude (p=0.13). 
In mean plasma LH, a significant day effect (p=0.02) was found. Mean plasma LH on Day 4 
was significantly higher than on Day 2. No housing effect (p=0.34) nor a significant 
interaction between day and housing (p=0.08) was found. 
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Table 2: Pulsatile LH release on Day 2 and 4 after altrenogest withdrawal in LOOSE and 
TETHER sows. 
Day 2 after altrenogest Day 4 after altrenogest 
LOOSE 
(n=12) 
TETHER 
(n=10) 
LOOSE 
(n=12) 
TETHER 
(n=10) 
pulse frequency (#/12h) 8.17±0.37 8.10±0.31 6.67±0.40 7.30±0.54 
pulse amplitude (ng. ml"1) 5.23±0.51 8.88±2.89 7.58± 1.35 24.3±5.62 
mean plasma LH (ng.ml"1) 8.25 ±1.62 14.5 ±2.64 10.0 ±2.00 26.4±5.04 
Data are presented as mean ± SEM. A day effect was found with LOOSE and TETHER animals having 
significantly higher pulse frequency but lower pulse amplitude and mean plasma LH on Day 2 than on Day 4 
(p<0.05). 
Since the occurrence of the preovulatory LH surge on Day 4 in 8 out of 22 animals could 
have interfered with data on LH pulse frequency, pulse amplitude and mean plasma LH, data 
were synchronized on the day of the preovulatory LH surge (Day 0) and analysed on Day -2 
and -3. As a consequence, the number of animals per treatment group decreased. No 
differences were found in LH pulse amplitude between Day -2 and -3 (p=0.64), nor between 
TETHER and LOOSE animals (p=0.91), nor an interaction between day and housing 
(p=0.92). However, LH pulse frequency tended to be higher on Day -3 than on Day -2 
(p=0.08), with no effect between housing conditions (p=0.75), nor an interaction between day 
and housing conditions (p=0.96). Mean plasma LH was lower on Day -3 compared to Day -2 
(p=0.03) relative to the preovulatory LH surge. No effect of housing nor an interaction 
between day and housing was found in mean plasma LH on these days (p=0.78; p=0.14). 
Table 3: Pulsatile release of LH on Day -2 and -3 relative to the preovulatory LH surge in 
LOOSE and TETHER sows 
Day -3 relative to LH surge Day -2 relative to LH surge 
LOOSE 
(n=6) 
TETHER 
(n=3) 
LOOSE 
(n=6) 
TETHER 
(n=7) 
pulse frequency (#/12h) 8.00 ±0.58 9.00±0.00 6.83 ±0.75 7.71 ±0.36 
pulse amplitude (ng. ml'1) 4.88 ±0.75 5.15 ±1.56 6.86 ±2.35 10.5 ±4.01 
mean plasma LH (ng.ml"1) 6.91 ±0.73 7.79±2.22 10.6±4.02 17.4±3.10 
Data are presented as mean ± SEM. No day or housing effects are found in LH pulse frequency and pulse 
amplitude. Mean plasma LH in LOOSE and TETHER animals is significantly lower (p<0.05)on Day -3 than on 
Day -2 relative to the preovulatory LH surge 
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Discussion 
Long-term tethered housing induces chronic stress in pigs, and leads to stress-adaptive 
changes in physiological regulation that may become apparent upon environmental challenge. 
In the present study, we have investigated the effect of a change in housing conditions on the 
hypothalamus-pituitary-gonadal (HPG) axis in multiparous stress-adapted female pigs. 
During the luteal phase, the LOOSE group of animals showed lower mean plasma LH levels 
than the THETHER animals, whereas LH pulse frequency and amplitude were not affected 
by housing condition. Sofar, no overt effects of chronic tethered housing on plasma LH 
concentration in females have been reported. Studies in rats and rhesus monkeys showed 
decreased plasma LH concentrations after restraint stress (Tache, et al, 1978; Goncharov et 
al, 1984; Lopez-Calderon et al, 1987), however, they used male subjects and chronic 
intermittent immobilisation stress. 
Both groups of sows used in the present study had a history of long term tethered housing 
during which adaptational processes in the regulation of the hypothalamus-pituitary-adrenal 
(HPA) axis, autonomic nervous system and behaviour occur, rendering the pigs more reactive 
to changes in environmental conditions (Schouten et al, 1991; Janssens et al, 1994; Janssens 
et al, 1995a; Clark et al, 1997). The change in housing conditions of the LOOSE sows, that 
were able to move freely from approximately 6 weeks before the start of the experiment 
onwards, likely was a challenge for the animals, inducing changes in mean LH concentration . 
In a study by Rampacek et al. (1984), a change from confined to non-confined housing also 
resulted in a change in LH plasma concentration. The fact that they found an increase in 
plasma LH concentrations in the non-confined group, whereas our results show decreased LH 
levels in the LOOSE animals may be explained by the fact that, apart from methodological 
differences, they used prepubertal pigs, that is animals in which the regulation of LH differs 
considerably from that in multiparous sows as used in the present study. 
LOOSE pigs showed a significant delay of the preovulatory LH surge with 25 hours. It could 
be argued that this was caused by a difference in activation of the HPA-axis. Janssens et al. 
(1995a) reported a flattened diurnal rhythmicity of Cortisol and a hypercortisolemia during 
long-term tethering. These changes, however appeared to be of a transient nature, indicating 
development of adaptational changes in the HPA system at least in part of the animals. In the 
present study, plasma Cortisol concentrations were not different between housing conditions, 
but, relatively high when compared to those of the loose housed controls in studies by 
Janssens et al. (1994; 1995a). In addition, there was no indication of a diurnal Cortisol rhythm 
in both the LOOSE and the TETHER animals. Therefore, the shift in the preovulatory LH 
surge cannot be explained by a difference in activation of the HPA axis. Furthermore, from 
the present data together with those from the literature, it might be suggested that LOOSE 
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animals are in a transitional state, during which changes in the HPG- but not the HPA-system, 
induced by previous long term tethered housing, are reversed towards pretethering levels. 
Pulse frequency decreased while pulse amplitude and mean plasma LH increased from the 
early (Day 2 after altrenogest withdrawal) towards the late follicular phase (Day 4 after 
altrenogest withdrawal) irrespective of housing condition. When data were lined up to the day 
of the preovulatory LH surge, this pattern was still largely present with a significant time 
effect in mean plasma LH concentration and a trend in pulse frequency. These findings are in 
line with other studies showing higher pulse frequency with low amplitude in early follicular 
phase compared to mid- and late follicular phase (Kesner et ai, 1989; Messinis et ai, 1992; 
Matt et ai, 1993) depending on the presence of gonadal steroids. 
In summary, the present study shows that a change in housing conditions delays the 
preovulatory LH surge and decreases the mean LH concentration during the luteal phase, but 
has no effect on LH pulse frequency and pulse amplitude under progesterone dominance with 
altrenogest and during both phases of the oestrus cycle after termination of altrenogest 
treatment. 
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Abstract 
The response of the reproductive axis to endogenous opioid peptides (EOP) was investigated 
by determining the increase in mean plasma LH concentration after intravenous 
administration of 5 doses of the opioid antagonist naltrexone using PRL as a positive control-
Cyclic gilts received iv treatment with saline or 0.125, 0.25, 0.5, 1 or 2 mg/kg naltrexone 
during the luteal phase of the oestrous cycle and frequent bloodsamples were taken. On 
average, plasma LH and PRL concentrations increased with increasing dose of naltrexone in 
the first hour postinjection. Plasma LH concentration was increased (P<0.05) after 0.25 and 
2 mg/kg naltrexone compared to control, whereas plasma PRL concentration was increased 
after all doses used. However, a considerable variation between animals was found in the 
response of both hormones with 2 animals showing no response to the doses used, 2 animals 
responding to 0.25 mg/kg and higher, and 3 animals responding to all doses. The 5 
"responders" showed increased plasma LH concentrations during the first hour postinjection 
after 0.25, 0.5 and 2 mg/kg naltrexone. Over the total postinjection period 2 mg/kg naltrexone 
increased plasma LH concentration compared to all other doses (P<0.05) except 0.5 mg/kg. 
During the first hour postinjection, the 5 "responders " showed increased (P<0.05) plasma 
PRL concentration after all doses used 
In conclusion, naltrexone dose dependently increased the mean plasma LH and PRL 
concentration with a considerable variation between animals. Furthermore, it is suggested 
that the LH and PRL response differ in sensitivity to inhibition by EOP's. 
Introduction 
Endogenous opioid peptides (EOP's) are involved in the regulation and the pulsatile secretion 
of luteinizing hormone (LH). Intravenous treatment with opioid receptor antagonists has been 
shown to increase plasma LH concentration in primates (Mello et at., 1988), sheep (Whisnant 
et al., 1991), humans (Gindoff et la., 1988, Remorgida et al, 1990), rat (Babu et al, 1988) 
and pig (Barb et al., 1985). In the pig, intravenous infusion with a met-enkephalin analog 
decreased mean LH concentration (Okrasa and Tilton, 1992). Furthermore, B-endorphin and 
leu-enkephalin have been reported to inhibit the LH release from rat pituitaries in vitro (Leiva 
and Croxatto,1994). Studies by Barb et al. (1986) in pigs and by Stumpf et al. (1993) in 
ovariectomised beef cattle have shown that the reduction of plasma LH concentration by 
progesterone was counteracted by the administration of the opioid receptor antagonist 
naloxone. This strongly suggests that the inhibition of plasma LH concentration by 
progesterone is mediated by an opioidergic mechanism. 
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A technical problem in studying effects of EOP's on the plasma LH concentrations is the 
pulsatile pattern which might obscure the response to opioid antagonists. The concentration of 
PRL in plasma, like that of LH, is under inhibitory control of EOP and has been reported to 
increase after naloxone treatment (Snowden et al, 1984; Barb et al., 1986). This together 
with the fact that PRL release does not follow pulsatile kinetics, makes the plasma PRL 
concentration suitable as a positive control for the effect of drugs that interfere with the 
opioid regulation of LH secretion system. 
A considerable variation between individual animals in the response to opioid receptor 
agonists and antagonists appears to exist. Deroche et al. (1993) showed differences in 
locomotor response to morphine treatment between individual rats. Martin del Campo et al. 
(1992) reported large individual differences in naloxone induced rise in plasma Cortisol in 
humans, and Raevskaia, (1992) has shown in rabbits that the naloxone induced hyperalgesic 
effect depended on individual properties of the animals. Therefore, it might be useful to 
check whether individual variability in response to opioid agonist and antagonists is related to 
the plasma concentrations of the drugs used. 
The aim of the present study was to investigate the response of the reproductive axis to EOP's 
by determining the increase in mean plasma LH concentration after intravenous 
administration of saline or 5 doses of naltrexone in gilts. Mean plasma PRL concentration is 
used as a positive control and plasma concentrations of naltrexone were determined to check 
adequacy of treatment. 
Materials and methods 
Animals 
Seven crossbred cyclic gilts (Great Yorkshire X British Landrace; Pig Improvement 
Company, Oxfordshire, United Kingdom) which had shown two or more normal oestrous 
cycles were used in this study. At the start of the experiment, mean body weight of the 
animals was 192.6 ±6.1 kg (mean ± SD). All animals were housed loose in individual pens 
with a concrete floor that was covered with woodshavings, except for a slatted dunging area 
at the rear of the pens. Lights were on from 7.30 h to 19.30 h and ambient room temperature 
ranged from 15°C to 25 °C. At 8.00 h and 16.00 h the gilts were fed 1 kg of a pelleted, dry 
sow feed (12.2 MJ of metabolizable energy per kilogram containing 15.4% crude protein) by 
hand. Water was available ad libitum through a drinking nipple. 
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Surgery 
In order to collect frequent blood samples, the gilts were surgically fitted with a permanent 
jugular vein catheter (Silastic® medical grade tubing, 0.040 in. i.d., 0.085 in. o.d.; Dow 
Corning, Michigan U.S.A.) under sterile conditions, and under general anaesthesia with 
inhalation of 02/N20, enflurane Ethrane®, Abott B.V., The Netherlands) as described 
previously (Janssens et al., 1994) with slight modification in the attachment of the catheter to 
the jugular vein. The animals were equipped with a harness to protect the cannula, which was 
externalized between the scapulae. The harness (23 cm x 20 cm, polyvinyl chloride with 
nylon; Bizon Chemie, The Netherlands) was fixed at the back of the animals with a belt 
around the chest during the week before surgery in order to habituate to the harness. All 
animals were treated with antibiotics (12 ml of T.S. Sol®, containing trimethorprim and 
sulfamethoxazol, orally; Dopharma, The Netherlands) once daily from 3 days before surgery 
until 3 days after surgery. The animals were allowed to recover from surgery and anaesthesia 
for at least 10 days. 
To prevent obstruction by bloodclots, the catheters were flushed with saline once weekly and 
filled with heparinized saline (25 IU heparin/ml of 0.9% saline; Leo Pharmaceutical Products, 
The Netherlands) when not in use. When catheter patency was reduced, obstructions were 
removed as described by Leuvenink and Dierx (1997). In short, a solution of 25000 IU 
kabikinase (Kabi Pharmacia, Sweden), 2500 IU heparin and 0.2 ml Ticarpen® (Beecham, 
England) was added to 25 ml sterile 25% PVP/saline (Merck, Germany) solution. After 1 
week, the catheter was flushed with a 2% heparine/saline solution. 
Experimental procedure 
In all 7 gilts, the effect of 5 doses of naltrexone (0.125 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 
mg/kg and 2 mg/kg) on the plasma concentration of LH was tested and compared to 5 ml 
saline (control) with a washout period of 7 days. Each animal received all doses in a random 
order over a total period of 4 oestrus cycles (2 doses/ cycle) and each animal served as its 
own control. The first day of oestrus was designated as Day 0. On Days 7 and 14 (luteal 
phase), blood samples were collected every 12 minutes for 8 hours (from 9.00 h until 17.00 
h) according to the procedure described previously (Janssens et al, 1994). The samples of the 
first two hours (9.00 h - 11.00 h) were used to determine the basal LH release and at 11.00 h, 
saline or one of the doses naltrexone (Sigma Chemicals, St Louis, U.S.A.) was injected given 
as an iv. bolus via the catheter. 
Blood sampling procedure 
Before the experiment, the animals were frequently handled and habituated to the blood 
sampling procedure. Immediately after collection, the blood samples (approximately 5 ml) 
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were transferred to ice-cooled polypropylene tubes containing 50 ml EDTA solution (144 mg 
EDTA/ml of saline; Triplex®III, Merck Nederland BV, The Netherlands). The tubes were 
mixed, placed on ice, and subsequently centrifuged at 3000xg for 15 min at 4°C. Plasma was 
collected and stored at -20°C until hormone analysis. 
Plasma analysis 
Plasma samples were analysed using validated immunoassays for LH (Niswender et ai, 
1970), PRL (Van Landeghem and Van der Wiel, 1978) and progesterone (Helmond et al, 
1980). All samples were analysed for LH, whereas PRL was determined in plasma samples of 
9.24 h, 10.00 h, 10.36 h and every 12 minutes from 11.00 until 12.00 (first hour after 
injection). Plasma levels of progesterone were determined in 10.00 h, 12.00 h, 14.00 h and 
16.00 h samples. The intra- and inter-assay coefficient of variation was 7.2 and 14.4%, 6.9 
and 12.3% and was 5.5% and 12.2%, respectively, for LH, PRL and progesterone. 
Plasma concentration of naltrexone was determined by a HPLC method used for detection of 
morphine described previously by Joel et al. (1988), which has been modified by using 100 
mg Varian C8 extraction cartridges, and the use of an ASPEC automated sample preparation 
device. The samples were eluted with 15% acetonitrile instead of 10% acetonitrile to improve 
extraction efficiency up to 75%. 
Animals that showed an increase in plasma LH and PRL concentrations of at least 150% of 
baseline concentration within the first hour after iv treatment with naltrexone, were qualified 
as responders. Animals that did not meet this criterion even at a dose of 2 mg/kg naltrexone, 
were qualified as non-responders. 
Detection ofoestrous 
Detection of oestrous was performed once daily in the morning on all days of the cycle by a 
back-pressure test in the presence of a vasectomized boar. The time of oestrous was defined 
as the day the gilt showed a standing response to the back-pressure test in the presence of the 
boar. 
Statistical analysis 
LH concentration of all samples was expressed as a percentage of the average basal release. 
In order to describe the time course of the mean plasma LH concentration after treatment with 
saline or the several doses of naltrexone, the experiment days were divided in 8 Time Periods 
(TP's) of 1 hour. Data of mean plasma concentration of LH, PRL and progesterone were 
analysed using SAS statistical analysis system (1990). The effect of the several doses of 
naltrexone was tested by means of a F-test, using the procedure GLM and the following linear 
model: Y^ = m + Aj + N; + TP^ + (NxTP)^ + IT\ + e ^ ; Where Yyy= value of hormone 
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parameter in gilt i treated with dosis j at injection time k in an oestrous cycle; m = overall 
mean; Aj = fixed effect in animal i (i = 1,..,7); N; = fixed effect of dosis j (j = 1,...,6); TP^ = 
fixed effect of time period k (k = 1,...,8); ITj = fixed effect of first or second injection k (k = 
1,2) within an oestrous cycle; ej.-y = error term, which represents the random effect of dosis j 
in animal i at and first or second injection 1 within an oestrous cycle. Differences were 
considered significant when P<0.05. Values are expressed as means and standard error of the 
means. 
Results 
Plasma hormone concentrations 
In none of the parameters studied, namely plasma LH, PRL and progesterone concentration, 
interactions were found between iv treatment and injection time (day 7 or day 14 after first day 
of oestrus). Furthermore, sequence of administration of the doses naltrexone or saline had no 
effect on these parameters. 
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Figure 1: Illustrative profiles of the average LH levels of 7 gilts. Profiles of pulsatile LH release of 5 gilts 
(average ± SEM) treated with (A) saline, (B) 0.5 mg/kg and (C) 2 mglkg naltrexone. Data are presented as % 
of basal release and relative to time of injection (t=0). 
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The high level of progesterone in bloodplasma of all animals (53.6 ± 1.0 ng/ml; n=7), 
indicated that all the experimental days were during the luteal phase. There were no differences 
between plasma levels of progesterone before and after treatment with naltrexone (50.6 ± 2.5 
ng/ml vs 53.2 ± 2.6 ng/ml) or saline (54.5 ± 8.5 ng/ml vs 53.9 ± 6.3 ng/ml). 
Plasma concentrations of both LH and PRL during the first hour after injection increased with 
increasing dose of naltrexone (Figure 2), returning to preinjection levels within the sampling 
period except for LH after administration of the highest naltrexone dose (as illustrated in 
Figure 1). The peak concentrations of LH and PRL after treatment with naltrexone were found 
within the first hour (on average after 24 ± 12 minutes; mean ± SEM) post injection of the 
opioid antagonist as is illustrated by Figure 1. The doses of 0.25 mg/kg and 2 mg/kg increased 
plasma LH concentrations significantly (p=0.05 and p=0.001 respectively) compared to 
control, whereas plasma PRL concentrations were significantly (p<0.05) increased by all doses, 
except 0.125 mg/kg (figure 2). 
A considerable variation between animals was found in the LH and PRL response to the 
several doses of naltrexone. Out of 7 animals, 2 showed neither a LH, nor a PRL response at 
any of the doses used and were therefore qualified as non-responders. Furthermore, 2 animals 
showed significant LH and PRL responses to doses of 0.25 mg/kg and higher, and 3 animals 
responded to all doses and might be qualified as "low responders" and "high responders" 
respectively. 
Plasma naltrexone 
Plasma concentrations of naltrexone increased proportional to the dose in all animals (Figure 
2). Plasma concentrations of naltrexone after the doses of 0.5 mg/kg and 1.0 mg/kg were two 
respectively four times the plasma concentrations after the dose of 0.25 mg/kg naltrexone. The 
absence of response in 2 animals could not be attributed to the absence of naltrexone in the 
blood, indicating they were not responding to naltrexone. Data of the other 5 animals that did 
show a response in LH and PRL were subjected to further analysis. 
Plasma hormone concentrations of responders 
A treatment effect in mean plasma LH during the first hour post injection was found (P<0.002; 
Table 1). Compared to saline, mean plasma LH was significantly increased after treatment with 
the doses 0.25 mg/kg, 0.5 mg/kg and 2.0 mg/kg (P<0.05). Furthermore, the dose of 2.0 
mg/kg, significantly increased mean plasma LH (P<0.05) compared to the other doses used 
except 0.25 mg/kg and 0.5 mg/kg (Table 1). 
During the second and third hour post injection, when plasma levels were decreasing towards 
preinjection levels, the effect of naltrexone on LH levels was still found, but not statistically 
significant. During the fourth hour post injection, saline treated animals showed significantly 
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Figure 2: Hormone and naltrexone concentrations in plasma of 7 gilts. Data are presented as mean ± SEM. 
Concentration of LH (ng/ml; upper panel), PRL (ng/ml; middle panel) and naltrexone (ng/ml; bottom panel) 
during the first hour after iv treatment with saline or several doses of naltrexone. 
* =p<0.05from saline (P<0.05) 
higher mean plasma LH (257 ± 124 ng/ml; mean ± SEM) than animals treated with 0.125 
mg/kg (77.8 ± 5.56 ng/ml), 0.25 mg/kg (104 ± 26 ng/ml), 0.5 mg/kg (147 ± 29.6 ng/ml) and 1 
mg/kg (126 ± 88.7 ng/ml) naltrexone except for the highest dose (210 ± 52.5 ng/ml). During 
the fifth hour PI, this pattern was similar, but the differences were not significant. 
When the total post injection period (6 hours) was analysed, mean LH plasma concentration 
over this period showed a significant treatment effect (Table 1; P=0.01). Treatment with the 
2.0 mg/kg dose of naltrexone resulted in significantly higher mean plasma LH concentration 
than all other doses (P<0.05) except 0.5 mg/kg. 
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A significant treatment effect (P=0.0001) was found in plasma PRL levels (Table 1). Plasma 
PRL levels were significantly (P<0.05) increased by naltrexone in all doses in the first hour 
post injection. 
Table 1: LH release in responders following iv. administration of several doses of naltrexone. 
dose 
saline 
0.125 mg.kg"1 
O^Smg.kg-1 
0.5 mg.kg"! 
l.Omg.kg"1 
2.0 mg.kg"1 
Mean plasma LH 
first hour PI' 
(%basal, n=5) 
104 ±22" 
167±34"b 
302 ± 96bc 
317±91 b c 
220 ± 89"b 
470 ± 99c 
Mean plasma 
PRL first hour 
PI1 (%basal, n=5) 
101 ±3.49" 
177 ± 17.4b 
174±13.3 b 
197±19.1 b 
188 ± 20.3 b 
201±20 .2 b 
Number of 
responders 
(n out of 5) 
0 
3 
5 
5 
5 
5 
Mean plasma 
LH 
total period PI 
(%basal, n=5) 
162 ±35" 
119± 15' 
191 ±53" 
199±44"b 
152 ±52" 
290 ± 63b 
Data are presented as means ± SEM. Numbers in columns with the same superscript letter (a,b,c) are not 
significantly different (P>0.05). lMean plasma levels ofLH and PRL during the first hour postinfection 
period (% of basal); Number of animals that responded to treatment with saline or the several doses 
naltrexone during the first hour postinfection; Mean plasma LH concentration during the 6 hours postinjection 
period (% of basal). 
Discussion 
There appeared to be a considerable individual variation in the response to naltrexone, as is 
reflected by the "non-responding" and "responding" animals, although all animals clearly 
showed increasing plasma concentrations of naltrexone with increasing dose. Within the 
group of "responders", there were three animals that showed an increased plasma LH 
concentration the first hour already after injection of the lowest dose of naltrexone (0.125 
mg/kg), whereas the two other pigs showed the first increase at 0.25 mg/kg of the opioid 
receptor antagonist. In line with this, studies in rats (Deroche et ai, 1993; Morgan and Picker, 
1996), humans (Martin del Campo et al., 1992) and rabbits (Raevskaia, 1992), have reported 
a considerable individual variation in behavioural responses after treatment with the opiate 
drug morphine, or the opioid receptor antagonist naloxone. These and the present findings 
show that, when using opioid receptor anta- or agonists, data of the individual animal should 
be considered with the interpretation of group data. 
In the responders, a dose-dependent effect of naltrexone on mean plasma LH during the first 
hour post injection was found. However, the dose of 1 mg/kg showed a (not significant) 
lower response compared to 0.25 mg/kg and 0.5 mg/kg. A similar phenomenon was reported 
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by Taylor et al. (1991), who found less attenuation of self-injurious behaviour in humans 
after treatment with 1 mg/kg naltrexone compared to treatment with 0.5 mg/kg. This "dip" in 
the dose-response could not be attributed to the dosage or the bioavailability of naltrexone 
since plasma concentration increased with increasing dose. At present, we were not able to 
find a gratifying explanation for this phenomenon. 
Naltrexone increased plasma PRL levels during the luteal phase of the oestrous cycle. These 
results are in agreement with studies by Gold et al. (1979), Snowden et al. (1984) and Barb et 
al. (1985) that have shown increased PRL release during the luteal phase of the oestrous cycle 
after iv. treatment with naloxone in primates, humans and pigs respectively. The effectiveness 
of naltrexone to increase PRL levels over the complete dose range used, and the absence of a 
clear dose-response relationship for this effect, validate the use of the PRL-response as a 
positive control for the effectiveness of the treatment. Yet different mechanisms may underlie 
the naltrexone effect on PRL and LH. 
Mean plasma LH concentration over the total 6 hour postinjection period increased with 
increasing dose of naltrexone, showing a similar pattern as during the first hour post injection 
period. Saline treatment, however, showed relatively high mean plasma LH concentration 
during this period. This was caused by an endogenous LH pulse that occurred in the third 
hour post injection in 6 out of 7 animals. This phenomenon was not observed after treatment 
with naltrexone (data not shown). It might be suggested that the administration of naltrexone 
increased LH release directly after injection, thereby reducing the GnRH and/or LH 
releasable pool and the ability of the hypothalamus and/or pituitary to respond to the 
endogenous rhythm of pulsatile LH release. 
In summary, iv. administration of naltrexone increases the plasma concentrations of LH and 
PRL with PRL responding to a lower dose than LH. In addition, a considerable variation 
between animals in the LH and PRL response to naltrexone was observed. 
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Abstract 
The role of endogenous opioid peptides (EOP) in modulating the pulsatile LH release during the 
follicular phase was investigated in 5 chronically tethered and 8 loose housed gilts. Oestrous 
cycles of all animals were synchronised with altrenogest for 21 days. Subsequently, 3 tethered and 
4 loose housed gilts were treated per os with opioid receptor antagonist naltrexone for 6 days with 
the remaining animals serving as controls. Frequent bloodsamples were taken on Days 2, 4, 5 and 
6 after termination of altrenogest treatment. No effects of housing condition on the pulsatile LH 
release were found. LH pulse frequency did not differ between days in the naltrexone treated 
animals but was decreased (P<0.05) on Day 4 and 5 compared to Day 2 and 6 in control animals. 
LH pulse amplitude and area under the pulse (AUP) were higher (P<0.05) on Day 6 than on all 
other days in control animals. In naltrexone treated animals, LH pulse amplitude and AUP were 
higher on Day 5 but only significant compared to Day 4 (P<0.05). No effects of naltrexone 
treatment were found on all parameters when data were lined up to the first day of oestrus. 
Oestradiol concentration was lower on Day 2 compared to Day 5 and higher in control compared 
to naltrexone treated animals (P<0.05). In addition, oestradiol concentration was negatively 
correlated with LH pulse frequency. 
In summary, after pulses of high frequency and low amplitude during early follicular phase, pulse 
frequency decreases until the day of the preovulatory LH surge. This pattern does not seem to be 
modulated by EOP's. 
Introduction 
LH secretion during the oestrous cycle has been studied in a variety of species as sheep (Whisnant 
et al, 1991), human (Fillicori et al, 1986; Rossmanith et al, 1990), pig (Okrasa and Tilton, 1992) 
and primate (Norman et al, 1994). Relatively few data are available, however, on the pattern of 
pulsatile LH release during the follicular phase, particularly with regard to pulse frequency and 
pulse amplitude. Reame et al. (1994) and Rossmanith et al. (1990) showed an increased pulse 
frequency in the late compared to the early follicular phase in humans, whereas Cagnacci et al. 
(1995) did not find significant differences in pulse frequency between these phases of the follicular 
phase in women. 
Plasma LH release has been shown to be decreased by endogenous opioid peptides (EOP's) in a 
variety of species. EOP's are reported to mediate the negative feedback of progesterone during the 
luteal phase (Yang et al., 1988; Barb, et al, 1992; Kaynard et al., 1992). The stimulatory effect of 
opioid receptor antagonists, like naloxone and naltrexone on plasma LH concentration during this 
phase of the oestrous cycle has been reported in numerous studies (Whisnant and Goodman, 1988; 
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Kaynard et al, 1992; Chang et al, 1993; Heisler et al, 1993). However, whether EOP's play also 
an inhibitory role in LH secretion and/or the timing of events leading to the preovulatory LH surge 
and oestrus during the oestradiol dominated follicular phase, still remains to be elucidated. 
Several studies have shown that the LH release is decreased by stress, suggesting an inhibitory role 
of EOP's, which have been shown to be activated during stress (Rivier and Rivest, 1991; Heisler et 
al, 1993; Norman et al, 1994). Furthermore, in pigs, it has been shown that tethered housing 
induces chronic stress. Thus, it increases adrenocortical sensitivity to ACTH, its steroidogenic 
capacity and plasma concentrations of Cortisol and PRL (Janssens et al, 1995a). Furthermore, 
tethering increases endogenous opioid activity (Janssens et al, 1994; Schouten and 
Wiepkema, 1991), the number of u-opioid receptors in the brain (Zanella et al, 1996), and it 
leads to opioid dependent stereotyped behaviour (Cronin, 1985; Schouten and Wiepkema, 
1991). However, the effects of tethered housing on the plasma LH concentration and 
pulsatile LH release during the oestrous cycle, and the follicular phase in particular is, are not 
known. 
The purpose of the present study was to determine the pulsatile pattern of LH release during the 
follicular phase of the oestrous cycle, and to investigate the role of EOP's in modulating this 
pattern by treating loose or tethered housed gilts orally with the opioid receptor antagonist 
naltrexone. 
Materials and Methods 
A nimals and Housing 
Thirteen healthy cyclic cross-bred gilts (118-145 kg body weight; Great Yorkshire x British 
Landrace, Pig Improvement Company, UK) were used in this study. Five pigs were housed 
tethered by a 50 cm heavy-gauge neck-chain in individual tether stalls, each 65 cm wide for 5 
months prior to and during the experiment. During the same time, eight gilts were housed loose in 
individual pens of 5 to 6 m with a concrete floor that was covered with wood shavings, except for 
a slatted dunging area of 2.5 m at the rear of the pens. In all housing conditions lights were on 
between 7.30 h and 19.00 h and ambient temperature ranged from 15 to 25 °C. At 8.00 h and 
15.00 h the gilts were fed 1 kg of a pelleted, dry sow feed (12,2 MJ of metabolizable energy per 
kilogram containing 15.4% crude protein) by hand. A bell signal was given each time just before 
feeding in order to prevent the gilts from associating the presence of people with feeding. Water 
was available ad libitum through a nipple drinker. 
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Surgery 
In order to collect frequent blood samples, the gilts were fitted surgically with a permanent jugular 
vein catheter (silastic® medical grade tubing, 0.040 in. i.d., 0.085 in. o.d.; Dow Coming, 
Michigan, U.S.A.) under sterile conditions and under general anaesthesia with inhalation of 
02/N20, enflurane (Ethrane®, Abort BV, The Netherlands) as described previously (Janssens et 
al, 1994). The animals were equipped with a harness to protect the catheter, which was 
externalized between the scapulae. The harness (23 cm x 20 cm, polyvinyl chloride with nylon; 
Bizon Chemie, The Netherlands) was fixed at the back of the pigs with a belt around the chest 
during the week before surgery in order to habituate the animals to the harness. All animals were 
treated with antibiotics (12 ml of T.S. Sol®, containing trimethoprim and sulfamethoxazol, orally; 
Dopharma, The Netherlands) once daily from 3 days before surgery until 3 days after surgery. The 
gilts were allowed to recover from surgery and anaesthesia for at least 10 days before 
experimentation was started. 
To prevent obstruction by bloodclots, the catheters were flushed with saline once weekly and filled 
with heparinized saline (25 IU heparin/ml in 0.9% saline; Leo Pharmaceutical Products, The 
Netherlands) when not in use. 
Treatment 
The oestrous cycle of all gilts was synchronized by daily oral administration of 20 mg altrenogest 
(Regumate®, Hoechst Holland, The Netherlands), a progesterone agonist, during 21 days. The day 
after altrenogest treatment 4 loose housed and 3 tethered animals were treated for 6 days with the 
opioid receptor antagonist naltrexone.HC1 (Sigma Chemicals, St. Louis, U.S.A.) to investigate the 
involvement of EOP's in the regulation of the pulsatile LH release during the follicular phase. 
Naltrexone was given p.o. mixed with the feed. On day 1, 50 mg was given in the morning feed 
and in the afternoon feed as a loading dose. As a maintenance dose, 25 mg was given in the 
morning feed and 50 mg in the afternoon feed from day 2 to day 6. These doses of naltrexone 
were similar to those used by others in humans, to study the role of EOP's in amenorrhea induced 
by hyperprolactinemia and weight loss (Kremer et al, 1991; de Wit et al, 1991; Genazzani et al, 
1995). The control group of 4 loose housed and 2 tethered animals received no naltrexone 
treatment. 
The experiments were approved by the committee on animal care and the use of the Agricultural 
University, Wageningen, The Netherlands. 
Blood sampling 
Before the experiment, the animals were frequently handled and habituated to the blood sampling 
procedure. Blood samples (approximately 5 ml) were collected every 12 minutes during 12 hours 
(from 8.36 h to 20.36 h) on Day 2, 4, 5 and 6 after termination of altrenogest according to the 
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procedure as described previously (Janssens et al, 1994) and immediately transferred to icecooled 
polypropylene tubes containing 50 ml EDTA solution (144 mg EDTA/ml of saline; Triplex®IH, 
Merck Nederland BV, The Netherlands). The tubes were mixed, placed on ice, and subsequently 
centrifuged at 3000g for 15 minutes at 4°C. Plasma was collected and stored at -20°C until 
hormone analysis. 
Plasma analysis 
LH. Plasma samples were analysed for LH using a double-anti body radioimmunoassay as 
described by Niswender et al. (1970), using porcine LH (pLH iodination grade batch 004/3; 
potency, 0.85 x NIH LH-S19; UCB bioproducts, Brussels, Belgium) as a standard and for radio-
iodination (specific activity, 38 mCi/mg 125I-pLH). Anti-porcine LH batch 004 (UCB bioproducts, 
Brussels, Belgium) was used at a final dilution of 1:360,000, which gave an initial binding of the 
labelled hormone of approximately 39%. Sac-Cel® was used as the second antibody, (donkey anti-
rabbit; Wellcome Reagents, Beckenham). The main crossreacting peptides were pFSH (2.7%), 
pLHa (1.1%), pTSH (0.5%)and pTSHa, pTSHB and pLHB (all <0.1%). The minimal detectable 
dose at the 90% B/B0 concentration was 0.1 ng/ml. The inter-assay coefficient of variation was 
25.7% and the intra-assay coefficient of variation was 3.6%. 
Oestradiol. Plasma oestradiol concentration was measured in samples collected at 10.00 h, 12.00 
h, 14.00 h and 16.00 h. After extraction with dichloromethane (DCM, Merck, Darmstadt, 
Germany), using a single-antibody radioimmunoassay, 50 ml [2,4,6,7-3H]oestradiol (NEN 
Chemicals, 's Hertogenbosch, The Netherlands), was added to 650 ml plasma sample prior to 
extraction with 3 ml DCM to estimate procedural losses. The extracts were evaporated under a 
stream of nitrogen and the residues were redissolved in 500 ml ethanol 96%. An aliquot of 150 ml 
was taken to determine the recovery of [ HJoestradiol. Oestradiol concentrations were measured in 
150 ml aliquots by radioimmunoassay using a specific Rabbit antiserum raised against 6-keto-
oestrone 6-CMO-BSA. Oestradiol (Sigma Chemical Co., St. Louis, MO, U.S.A.) was used as a 
standard and [2,4,6,7-3H]oestradiol (specific activity, 95.4 Ci/mmol; NEN Chemicals) as a tracer. 
The main crossreacting steroids were oestrone (1.49%) and oestriol (0.21%). The antiserum was 
used at a final concentration of 1:125,000. The minimal detectable dose at the 90% B/B0 level was 
8 pg/ml. The interassay coefficient of variation was 17.4% and the intra-assay coefficient of 
variation was 12.4%. The concentration of oestradiol was expressed in pg/ml after correction for 
the procedural losses. 
Naltrexone. Plasma concentration of naltrexone was determined in samples collected at 8.36 h 
(30 minute after morning feeding), 15.36 h and 16.48 h (36 and 108 minutes after afternoon 
feeding respectively) by a HPLC method used for detection of morphine described previously 
by Joel et al. (1988), which has been modified by using 100 mg Varian C8 extraction 
cartridges, and the use of an ASPEC automated sample preparation device. The samples were 
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eluted with 15% acetonitrile instead of 10% acetonitrile to improve extraction efficiency up 
to 75%. 
Detection of oestrus 
Detection of oestrus was performed once daily in the morning on all days of the cycle by a back-
pressure test in the presence of a vasectomized boar. The time of oestrus was defined as the day 
the gilt showed a standing response to the back-pressure test in the presence of the boar. 
Pulse detection 
The profiles of LH release were analysed using the pulse analysis program of Maxima/Chromcard 
(Fisons Instruments.Interscience, Breda, Holland) with baseline calculated according to an 
algorithm taken into account the total profile. A pulse was defined by a baseline-peak ratio of 0.5 
or lower and a minimal area under the pulse of 6.0 x 106ng.ml'1.min. The highest value of a pulse 
above baseline was taken as pulse amplitude. 
Statistical analysis 
Data were analysed using SAS statistical analysis system (1990). The procedure GLM was used to 
analyse the linear model. Values are expressed as means ± standard error of the mean. The effects 
of naltrexone treatment, housing system, time (day after altrenogest withdrawal) and their 
interactions on the measured hormonal parameters were tested by means of an F-test using the 
following model with time data within gilts taken as repeated measurements. Y p = m + N; + Hj + 
(HxN)|j+ eUjk+ Ti+ (TxN)a+ (TxH)jj+ (TXNXH);JI+ 62^, where YjjW: value of hormone parameter 
at naltrexone treatment i, housing system j , for gilt k at sampling day 1; m = overall mean; N; = 
fixed effect of naltrexone treatment i (i = 1,2); Hj = fixed effect of housing system j (j = 1,2); eUjk = 
error term 1, which represents the random effect of gilt k within naltrexone treatment i and 
housing system j ; Tl = fixed effect of sampling day (1 = 1,...,4); 62^ = error term 2 which 
represents the random effect within gilts between sampling days. The effects of naltrexone 
treatment, housing system and their interactions were tested against error term 1. The other effects 
were tested against error term 2. Differences were considered significant when P<0.05, corrected 
for number of observations in the cases of interactions. The procedure CORK, was used to 
calculate Pearson's correlation coefficients. 
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Results 
General 
Of all 13 animals included in the experiment, 7 gilts showed a preovulatory LH surge within 
the period of sampling, with 4 out of 6 control animals on Day 6, and 2 out of the 7 
naltrexone treated animals on Day 5, and 1 animal on Day 6. On average the 13 gilts came 
into oestrus 6.8 ± 0.3 days after termination of altrenogest treatment. In the naltrexone treated 
group, there was a considerable variation among gilts in this respect (range: Day 5 to Day 9; 
Figure 1). With regard to the time of oestrus, no differences were found between loose and 
tethered housed animals. 
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Figure 1: First day of oestrus in control (upper panel) and naltrexone (lower panel) treated pubertal gilts, 
tethered (filled bars) or loose housed (open bars), after discontinuation of treatment with altrenogest. 
All animals gained weight during the experimental period of 5 months, with weight gain 
being significantly higher in loose housed (24 ± 1.7 kg) than in tethered gilts (16 ± 2.4 kg) 
(p=0.03). 
In all animals treated with naltrexone, plasma levels of the opioid receptor antagonist were 
readily detectable on Day 2 yielding a concentration of 9.6 ± 2.3 ng/ml (mean ± SEM) at 30 
minutes after the morning feeding, 11.6 ± 2.1 ng/ml and 9.9 ± 2.7 ng/ml at 36 minutes 
respectively 108 minutes after the afternoon feeding. In most of the samples taken at 
comparable timepoints on Day 6, the plasma concentration of naltrexone remained below 
detection (<2 ng/ml). Only 2 animals showed detectable but very low naltrexone 
concentrations, even after the high dose of 50 mg. 
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Figure 2: Illustrative profiles of pulsatile LH secretion and plasmalevels ofoestradiol of control (left) and 
naltrexone (right) treated pubertal gilts on day 2, 4, 5 and 6 after synchronisation of the oestrous cycle with 
altrenogest. 
Plasma LH 
Tethered housing did not affect pulse frequency (p=0.84), pulse height (p=0.71) and area 
under the pulse (AUP), nor was there an interaction effect between naltrexone treatment and 
housing (p=0.93; p=0.71 and p=0.40 respectively). For further analysis of the effect of 
naltrexone on LH pulse frequency and pulse amplitude during the follicular phase, the data of 
loose and tethered animals were pooled. Profiles of the pulsatile LH release are shown in 
Figure 2. Group data on pulse frequency and pulse amplitude are presented in Figure 3. 
A significant treatment x time interaction effect was found for pulse frequency (p=0.04). LH 
pulse frequency on Day 4 and 5 was significantly decreased compared to Day 2 and Day 6 
(the average day that the preovulatory LH surge occurred) in control animals (Figure 2 and 
3), whereas in naltrexone treated animals no differences were found between Days 2, 4, 5 and 
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6. Furthermore, pulse frequency in the naltrexone treated group was significantly lower 
compared to the control group on Day 2 after termination of altrenogest treatment (p<0.02). 
For pulse amplitude and AUP, a treatment x time interaction effect was found (p=0.0001; 
Figure 2 and 3). 
10 
9 
8 
7 
* + * 
r r t r 
2 4 5 6 
Day after termination of altrenogest treatment 
Figure 3: Data represent mean ± SEM ofLHpulse frequency (A; number per 12 h), pulse amplitude (B; 
ng/ml) and area under pulse (C; ng.ml .min) in control (closed bars) and naltrexone treated animals (open 
bars) during the follicular phase of the oestrous cycle. 
Time effect: 
* = significantly different from all others days within treatment group (P<0.05). 
** = significantly different from naltrexone treatment on Day 4 (P<0.05). 
*** = significantly different from control on Day 4 and 5 (P<0.05). 
Treatment effect: 
f = significantly different between treatment on the same day (P<0.05). 
In control animals, on Day 6 (the average day of preovulatory LH surge) pulse amplitude and 
AUP were significantly (both p=0.0001) higher compared to Day 2, 4 and 5. In naltrexone 
treated animals, pulse amplitude and AUP on Day 5 were significantly higher (both p=0.04) 
than on Day 4. In addition, compared to control animals, LH pulse amplitude and AUP in 
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naltrexone treated animals were significantly higher (both p=0.03) on Day 5 but significantly 
lower (both p=0.0001) on Day 6. 
To exclude the possibility that the effect of naltrexone was due to the occurrence of the 
preovulatory LH surge, data were lined up to the first day of oestrus. The effects of 
naltrexone found, when determined relative to altrenogest withdrawal, were not found when 
lined up to the first day of oestrus. LH pulse frequency (p=0.51), pulse amplitude (p=0.18) 
and AUP (p=0.23) in naltrexone treated animals were not different from control animals. 
Plasma oestradiol 
No difference was found in the plasma level of oestradiol between tethered and loose housed 
gilts (p=0.21), and therefore the data from tethered and loose housed animals were pooled for 
further statistical analysis. A clear-cut time-effect (p=0.0009) was found with significantly 
lower plasma levels of oestradiol on Day 2 (3.5 ± 1.1 pg/ml) compared to Day 4 (9.4 ± 1.7 
pg/ml; p=0.02), 5 (14.3 ± 2.2 pg/ml; p=0.0001) and 6 (11 ± 2.4 pg/ml; p=0.003) after 
termination of altrenogest treatment (see also profiles in Figure 1). In addition, on Day 4, 
oestradiol levels were significantly lower than on Day 5 (p=0.05). A treatment effect (p=0.03) 
was found, with naltrexone treated animals showing lower plasma levels of oestradiol (mean 
over Day 2 to 6: 7.4 ± 1.2 pg/ml) than control animals (12.3 ±1.8 pg/ml). 
Discussion 
The characteristics of the release of LH during the follicular phase of the oestrous cycle and the 
putative role of endogenous opioid peptides (EOP) in this respect, were investigated in loose and 
tethered housed gilts treated with the opioid receptor antagonist naltrexone. The follicular phase 
was characterised by highly frequent, low amplitude LH pulses on Day 2, followed by a decrease 
in pulse frequency on Day 4 and 5. The preovulatory LH surge occurred within 5-9 days after 
termination of altrenogest treatment, and was constituted of pulses of high frequency and high 
amplitude. The oestradiol concentration increased during the follicular phase with peak value on 
average on Day 5, the day before most of the control animals display the preovulatory LH surge. 
Furthermore oestradiol was negatively correlated with pulse frequency, which might reflect a 
negative feedback on the level of the hypothalamus. This would be in line with findings of Tanaka 
et al. (1992) and O'Byrne et al. (1993), showing decreased multi-unit activity in the mediobasal 
hypothalamus of oestradiol treated ovariectomized goats and monkeys, respectively. Thus, it 
might be suggested that oestradiol exerts its negative feedback, at least in part, by reducing GnRH 
pulse frequency at the level of the hypothalamus, and consequently the number of LH pulse 
secreted from the pituitary. 
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Abundant evidence exists reporting that stress can affect LH secretion and disrupt oestrous 
cyclicity (Fonda et al. 1984; Brann and Mahesh 1991; Rivier and Rivest, 1991). In our study, long 
term tethered housing did not influence LH pulse frequency, pulse amplitude and mean LH 
plasma concentrations in gilts during the follicular phase. In accord with the notion that tethered 
housing represents a chronic stressor, however, it did reduce body weight gain as compared to the 
loose housed condition. Thus, LH secretion in gilts may be relatively resistant to this form of 
housing stress. Alternatively, it could be that adaptive processes had occurred that maintained 
normal LH secretion under these conditions. Indeed, Janssens et al. (1995a) have shown that 
tethered housed gilts initially develop hypercortisolaemia and hyperprolactinaemia, but that these 
stress symptoms are temporary, and disappear after 3 months of tethering in at least part of the 
animals. In addition, they found evidence for adaptive changes in opioid mechanisms that could be 
instrumental in this respect. Furthermore, in Chapter II using multiparous sows, tethered housing 
as such did not change the frequency and amplitude of LH pulses but increased mean plasma LH 
concentration and advanced the preovulatory LH surge. Therefore, it might be suggested that 
tethered housing is not disrupting the pulse pattern of LH during the follicular phase, but, as 
suggested in a previous study (Chapter II), it might affect other processes like the timing of the 
preovulatory LH surge. 
In animals treated with the opioid receptor antagonist naltrexone, the timing of oestrus seemed to 
be shifted and possibly also the timing of the preovulatory LH surge. This is reflected by the lower 
pulse frequency and pulse amplitude in naltrexone treated pigs on Day 6, that is the day when the 
majority of the control animals displayed the preovulatory LH surge. This would be in support of a 
study by Faigon et al. (1987), who showed that in rats the "positive feedback" of the ovarian 
hormones on LH secretion is advanced by naloxone. In addition, Armstrong et al. (1988) 
reported that administration of morphine (sc) to sows for 5 days after weaning delayed the 
onset of oestrus, and other studies (Yearwood et al, 1991; Kraeling et al, 1992a) reported a 
delayed preovulatory LH surge in E2J3 primed OVX gilts after iv and ICV morphine 
treatment with no effect on the height of the surge. The present findings, together with data 
from the literature, might indicate that EOP activity is necessary for proper timing of events 
leading to the preovulatory LH surge. 
On Day 5, we found higher LH pulse amplitude and AUP in naltrexone treated animals 
compared to control animals. To determine whether this was caused by naltrexone treatment 
on this day or might have been due to the fact that 2 naltrexone treated animals showed the 
preovulatory LH surge on this day, data were lined up to the first day of oestrus. It appeared 
that naltrexone treatment had no effect on LH pulse amplitude and AUP, when data were lined 
up on the first day of oestrus. Therefore it might be suggested that naltrexone had no effect on LH 
pulse frequency, pulse amplitude and AUP but disrupted the timing of events leading to the 
preovulatory LH surge. 
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In the present study, repeated naltrexone administration did not result in a plateau level of 
naltrexone in plasma concentrations. Plasma concentrations of naltrexone decreased from 
detectable levels on Day 2 in all animals to concentrations below detection on Day 6 in most 
animals. This could not be attributed to the schedule of administration, since a plasma 
concentration of 3.2 ng/ml naltrexone would be expected on Day 6, using a mathematical 
approach. It could be suggested that plasma clearance of naltrexone is increased possibly by 
increased metabolic and/or renal clearance. From a study in humans by Vereby et al (1976) and 
Meyer et al, (1984), this was not expected since they reported a steady state equilibrium ranging 
approximately 2.5 ng/ml from the first day of administration until 18 days after a daily oral dose of 
100 mg. This might indicate a species difference in pharmacokinetics of naltrexone between pigs 
and humans. Furthermore it should be mentioned that, although plasma concentrations of 
naltrexone rapidly decrease to undetectable levels (i.e. <2 ng/ml), the opioid receptor antagonist is 
able to disrupt the timing of the preovulatory LH surge. 
In summary, after high frequency and low amplitude pulsatile LH release in the early follicular 
phase, pulsatility decreases until the day of the preovulatory LH surge. Oestradiol might modulate 
this pulse pattern of LH through EOP's on hypothalamic level since only LH pulse frequency is 
negatively correlated with plasma levels of oestradiol and naltrexone treatment disturbs the normal 
pulse pattern. 
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Abstract 
The aim of the study was to probe whether the responsivity of the pituitary to GnRH changes 
during the follicular phase, and whether this might be mediated by endogenous opioid peptides 
(EOP's). Oestrus cycles of 16 loose housed gilts were synchronized with altrenogestfor 21 days. 
Subsequently, 8 animals were treated per os with opioid receptor antagonist naltrexone for 6 days 
and 8 animals served as controls. On Days 2, 4, 5 and 6 after termination of altrenogest treatment, 
2 control and 2 naltrexone treated animals were killed. Trunk blood, ovaries and pituitaries were 
collected. Surge like levels ofLH were generally found on Day 6, but in 1 naltrexone animal on 
Day 5. Oestradiol concentration was highest on Day 4 and 5 and lowest on Day 6. Hemipituitaries 
were superfused and challenged with GnRH (10' M during 20 seconds) in vitro. In control 
animals, the LH response of hemipituitaries to GnRH was lowest on Day 4. In naltrexone treated 
animals, the LH response of hemipituitaries to GnRH was lowest on Day 2 and highest on Day 6. 
Furthermore, the LH response on Day 4 and 6 seemed to be higher in hemipituitaries of 
naltrexone treated than in control animals. Plasma LH concentrations showed a positive 
correlation with the hemipituitary LH response to GnRH in vitro and both parameters were 
negatively correlated with plasma oestradiol. It is suggested that pituitary responsivity to GnRH 
changes during the follicular phase and that EOP's modulate the timing of events that eventually 
lead to the preovulatory LH surge at the suprapituitary level. 
Introduction 
LH secretion during the oestrous cycle has been studied in a variety of species (Fillicori et al, 
1986; Whisnant et al., 1991, Okrasa and Tilton, 1992; Norman et al., 1994). During the luteal 
phase, LH pulses are of low frequency and high amplitude. This pattern changes to one of high 
frequency, low amplitude pulses during the early follicular phase, and then to high frequency, high 
amplitude pulses that constitute the preovulatory LH surge. These dynamics are thought to be 
determined mainly by a GnRH pulse generator at the hypothalamic level (Knobil, 1990; Veldhuis, 
1990). However, there is some evidence that the responsivity of the pituitary to GnRH changes 
throughout the oestrous cycle in the rat (Apfelbaum, 1981), and the menstrual cycle in humans 
(Rossmanith, 1991). Whether such changes in the responsivity of the pituitary for GnRH occur in 
the pig and contribute to the dynamics of plasma LH during the oestrous cycle, particularly during 
the follicular phase and the preovulatory LH surge, is unclear. 
Endogenous opioid peptides (EOP) have been implicated in the regulation of the pulsatile LH 
release, but their activity depends on the stage of the oestrous cycle (Kaynard et al., 1992; Chang 
et al., 1993; Heisler et al., 1993). There is considerable evidence for a tonic inhibition of LH 
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secretion by EOP's during the progesterone dominated luteal phase in sheep (Yang et al, 1988), 
pig (Barb, et al, 1992) and rat (Kaynard et al, 1992). Thus, it has been indicated that EOP's 
mediate negative feedback actions of progesterone. They do not seem to mediate, however, the 
negative feedback actions of oestradiol on LH release during the follicular phase (Barb et al. 1986; 
Seifer et al, 1990; Okrasa and Tilton, 1992). From recent studies, using rats and gilts treated with 
opioid receptor antagonists (ICV; per os), it was suggested that EOP's, rather than exerting a direct 
inhibition of LH release throughout the follicular phase, play a permissive role: termination of 
EOP-activity allows the preovulatory LH surge to be generated (Roozendaal et al, 1997; Chapter 
VII). A direct effect of naltrexone at the level of the pituitary, however, could not be excluded 
since it has been shown that opioid antagonists can increase LH release in pituitary cell cultures 
from pig, rat and cattle (Cacicedo and Franco, 1985; Blank et al, 1986; Barb et al, 1990). 
The present study was designed as a pilot study to probe whether the responsivity of the pig 
pituitary to GnRH changes during the follicular phase, and whether this might be mediated by 
EOP's. 
Materials and Methods 
Animals and housing 
The experiment was conducted with 16 crossbred gilts (Great Yorkshire x British Landrace; 
Pig Improvement Company, Oxfordshire, UK), weighing approximately 150 kg, which had 
shown 2 or more oestrous cycles of 19 to 21 days,. All animals were housed loose in 
individual pens (approximately 6 m2) with a concrete floor that was covered with wood 
shavings, except for a slatted dunging area at the rear of the pens. They were housed under a 
12:12 light:dark rhythm and ambient room temperature ranged from 15°C to 25°C. Pigs were 
fed 1 kg of a pelleted, dry sow feed (12.2 MJ of metabolizable energy per kilogram 
containing 15.4% crude protein) daily at 8:00 h and 16:00 h, and water was available ad 
libitum. 
Experimental design 
The oestrous cycles of all animals were synchronized by daily oral administration of 20 mg of 
the progesterone agonist altrenogest (Regumate®, Hoechst Holland, The Netherlands), added to 
the morning feeding for 21 days. Starting the day after last altrenogest treatment, 8 animals were 
treated twice daily for 6 days with the opioid receptor antagonist naltrexone.HCl (Sigma 
Chemicals, St. Louis, U.S.A.). Naltrexone was given p.o. mixed with the feed. On Day 1, 50 mg 
was given in the morning (8.00 h) and evening feed (16.00 h). From Day 2 to Day 6,25 mg was 
given in the morning feed and 50 mg in the evening feed. The control group of 8 animals received 
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no naltrexone treatment. On Day 2, 4, 5 and 6 after altrenogest withdrawal, 2 control and 2 
naltrexone treated animals were killed and pituitaries were quickly removed and kept on ice 
in culture medium. At slaughter, trunk blood was collected in cooled heparinized tubes, 
centrifuged at 3000xg for 15 minutes at 4 °C, and plasma was stored at -20 °C until 
radioimmunoassay of LH and E2fi (detection of the preovulatory LH surge and E2J3 peak). 
The ovaries were removed for follicle counts. The experiments were approved by the 
Committee on Animal Care and Use of the Agricultural University, Wageningen, The 
Netherlands. 
Superfusion 
Superfusion was performed using the method described previously by Verburg-van 
Kemenade et al. (1987b) with slight modifications. After removal of the posterior lobe, 
anterior pituitary glands were hemisected and each half was put in an air- and water-tight 
superfusion chamber (452 ul volume). The superfusion chambers were placed in a 
temperature controlled (38 °C) container. Culture medium consisted of Dulbeco's Modified 
Eagles Medium Nutrient Mix F12 (1:1) containing 0.356 %o L-Glutamine (w/v) and 15 mM 
HEPES with added per liter: 3.439 g TES, 35 mg Penicillin-G, 1 g NaHC03, 200 ul 0.25x10" 
%o gentamycin-sulfate, 500 ul ethanol, 50 ul catalase, 30.4 ul 0.1% (v/v) ethanolamine, 100 
ul 250 uM sodiumselenite, 100 ul 500 nM Tri-iodothyronin , 898,3 mg D-glucose, 5.0 g 
bovine serum albumin. In order to mimic in vivo conditions during the follicular phase, 
oestradiol-1713 (E2B) was added to the superfusion medium in concentrations matching those 
found in blood plasma on Day 2, 4, 5 and 6 respectively in a previous experiment with 
animals of the same breed, weight and treatment. Furthermore, superfusion medium of 
pituitaries from naltrexone treated animals, was supplemented with naltrexone in a 
concentration of 10"6 M. Medium was pumped at a speed of 80 ul/minute and superfusate was 
collected using a fraction collector (LKB type 3401B, Sweden). The first 100 minutes of 
superfusion were used to allow hormone release reach baseline values, and fractions of 10 
minutes collected during the following 100 minutes were used to determine basal LH release. 
Then hemipituitaries were superfused with culture medium containing 10' M GnRH during 
20 seconds (GnRH pulse), and 8 fractions of 2.5 minutes were collected. Thereafter, 10 
minute sampling was resumed and continued for another 140 minutes. Collected fractions 
were stored at -20 °C until hormone analysis. Basal LH release was determined by calculating 
the average LH concentration of the 10 fractions during the second 100 minutes of 
superfusion. The highest value measured during the 2.5 minute fractions following the GnRH 
pulse was used to calculate the LH response that was computed as % of basal. The procedure 
was validated for pig tissue by conducting a GnRH dose response curve and exposing the 
tissue to 60 mM KC1 to assess residual LH releasability (Dierx et al, unpublished results). In 
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the dose-response curve a maximal LH response was found at a GnRH concentration of 3.10"5 
M GnRH. In the present study a submaximal dose of 10" M was used to asses pituitary 
sensitivity for GnRH. 
Hormone analysis 
LH. Superfusion samples and trunk blood plasma were analysed for LH with a double anti-
body radioimmunoassay (RIA) as described by Niswender et al. (1970), using porcine LH 
(pLH iodination grade batch 004/3; potency, 0.85 x NIH LH-S19; UCB bioproducts, 
Brussels, Belgium) as a standard and for radioiodination (specific activity, 38 uCi/ug). Anti-
porcine LH batch 004 (UCB bioproducts, Brussels, Belgium) was used at a final dilution of 
1:360,000 yielding an initial binding (B0) of the labeled hormone of approximately 39%. 
Sac-Cel was used as the second antibody, (donkey anti-rabbit; Wellcome Reagents, Beckenham). 
The minimal detectable concentration at the 90% B/B0 level was 0.1 ng/ml. The interassay 
coefficient of variation was 14.4 % and the intra-assay coefficient of variation was 7.2 %. 
Oestradiol. Concentrations of E2B in trunk blood plasma were measured after extraction with 
dichloromethane (DCM, Merck, Darmstadt, Germany) using a single anti body 
radioimmunoassay. For estimation of procedural losses, 500 cpm of [2,4,6,7-3H]E2l3 (NEN 
Chemicals, 's Hertogenbosch, The Netherlands) was added to 1 ml plasma sample and mixed with 
3 ml DCM. The organic phase of the mixture was evaporated under a stream of nitrogen and the 
residue redissolved in 500 ul phosphate buffer with 1% BSA. An aliquot of 150 ul was taken to 
determine the recovery of [3H]E2B (57.7 ± 2.2%; mean ± SEM). Aliquots of 150 ul were used to 
measure E2B concentrations in duplicate by RIA using a specific rabbit antiserum against 6-keto-
estrone (6-CMO-BSA, UCB bioproducts, Brussels, Belgium) in a final dilution of 1:125,000. 
The mean crossreacting steriods were oestrone (1.49%) and oestriol (0.21%). E2-1713 (Sigma 
Chemical Co., St. Louis, MO, U.S.A.) was used as a standard and [2,4,6,7-3H]E2 (specific activity 
95.4 Ci/mmol", NEN Chemicals, 's Hertogenbosch, The Netherlands) as a tracer. The minimal 
detectable dose at the 90% B/B0 level was 8 pg.ml'1. The intra- and the inter-assay coefficient of 
variation 12.4 % and 17.4 % respectively. The concentration of E213 was expressed in pg.ml"1 after 
correction for procedural losses. 
Detection ofoestrous 
Oestrus detection was performed once daily in the morning after withdrawal of altrenogest 
treatment by a back-pressure test in the presence of a vasectomized boar. The time of oestrous 
was defined as the first day the sow showed a standing response. 
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Statistics 
The procedure CORR of the SAS statistical analyis system (1990) was used to calculate Pearson's 
correlation coefficients. 
Results 
General 
All 4 animals that were killed on Day 6 (2 control and 2 naltrexone treated animals) had 
shown oestrous behaviour on day 5. The ovaries of animals of the control group (N=8) were 
not different in weight (9.8 ± 2.7 g; P=0.67) or number of follicles (20 ± 1.4; P=0.46) 
compared to animals of the naltrexone treated group (N=8; 8.9 ± 0.69 g and 22 ± 1.4 
respectively). 
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Figure 1. Pituitary LH response to a GnRH pulse in superfused hemipituitaries. Data are presented as the 
mean value (% basal release/mg tissue) of 2 hemipituitaries from control (left panels) or 2 hemipituitaries 
from naltrexone (right panels) treated animals on Day 2, 4, 5 and 6 after termination of altrenogest treatment. 
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Plasma hormone concentrations in vivo 
The plasma E2J3 concentration, determined in trunk blood, in general reached the highest 
levels on Day 4 or 5 and were lowest on Day 6 (Table 1). On Day 2, 1 naltrexone treated 
animal had a relatively high plasma oestradiol concentration (89.9 pg/ml) and had follicles 
that were in developmental stage of Day 4. 
The LH concentration, determined in trunk blood, on average was higher in animals on Day 6 
than on Day 2, 4 and 5 (Table 1). One naltrexone treated animal already showed preovulatory 
surge-like LH concentrations on Day 5 (25.7 ng/ml). On Day 6 plasma concentrations of LH 
seemed to be lower in gilts of the naltrexone group compared to gilts in the control group. 
Table 1: Hormone parameters in vivo and in vitro in control and naltrexone treated animals 
Day after altrenogest treatment plasma LH plasma E2B LH response 
2 C 7~8 21 129 
C 1.6 <8 227 
N 2.7 90 85 
N 4.8 32 128 
4 C 23 44 109 
C 1.5 95 100 
N 2.5 41 121.0 
N 5.1 92 271 
5 C 2~2 85 139 
C 3.2 81 190 
N 4.3 118 122 
N 25.7 13 169 
6 C 15 l <8 248 
C 19.9 <8 161 
N 11.5 <8 204 
N 6.6 <8 324 
Data represent plasma LH concentration (ng/ml) in vivo, plasma E2fi concentration (pg/ml) in vivo, and 
pituitary LH response (% basal) to a GnRHpulse in vitro in individual control (C) and naltrexone (N) treated 
animals on Days 2, 4, 5 and 6 after termination of altrenogest treatment. 
LH response to GnRH pulse in vitro 
Data of the LH response of superfused hemipituitaries to GnRH are presented in Table 1 and 
illustrated by Figure 1. In control gilts the LH response seemed to be lowest on Day 4. In 
naltrexone treated gilts, the LH response seemed to be lowest on Day 2 and highest on Day 6. 
Furthermore, the LH response of hemipituitaries on Day 2 seemed to be lower in naltrexone 
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treated animals than in control animals. On Day 4 and 6, the LH response of hemipituitaries 
from naltrexone treated animals seemed to be higher compared to those from control animals. 
Correlations between in vivo and in vitro data 
The plasma LH concentrations showed a positive correlation with the pituitary LH response 
to GnRH (P=0.06, r2=0.48), and both parameters showed a negative correlation with the 
plasma E213 concentrations (P=0.04; r2=-0.52 and P=0.02; r2=-0.57 respectively). No 
correlations were found between the basal LH secretion in vitro and the plasma concentration 
of LH (P=0.56; r2=-0.16), the plasma concentration of E2B (P=0.79; r2=0.073), or the GnRH-
induced LH response in vitro (P=0.27; r =-0.29). 
Discussion 
The present study was designed as a pilot study to assess whether the LH response to a pulse 
of GnRH changes during the follicular phase and whether this is mediated by EOP's. The 
response of pituitaries of control animals seemed lowest on Day 4, and highest on Day 6, the 
day of the preovulatory LH surge as indicated by the high plasma LH concentration. 
Pituitaries of naltrexone treated animals showed an increase in LH response from Day 2 
reaching the highest response on Day 6. In view of the submaximal concentration of GnRH 
used, it is therefore suggested that, independent of the treatment with naltrexone, the 
responsivity of the pituitary increases from the follicular phase onwards reaching a maximum 
at the day of the preovulatory LH surge. This is in accord with studies from others that 
reported increased pituitary sensitivity to GnRH around the preovulatory LH surge in rats 
(Clayton et al, 1980; Apfelbaum, 1981) and humans (Rosemberg et al, 1974) and with data 
from the literature showing that E2B enhances the sensitivity of the pituitary for GnRH 
(Drouva et al, 1983; Koiter et al, 1987; Gregg et al, 1990), but inhibiting the LH secretion 
from the pituitary gonadotrophs (March et al, 1981; Knobil and Hotchkiss, 1988). Indeed, 
the negative correlations between the plasma E2B concentration and on the one hand plasma 
LH concentration and on the other hand the pituitary LH response in vitro in both treatment 
groups correspond with the presumed negative feedback by E2B reported in a variety of 
species in vivo (Helmond et al, 1986; Kesner et al, 1989; Messinis et al, 1992; Matt et al, 
1993). 
Naltrexone treatment seemed to affect the pituitary LH response to GnRH during the 
follicular phase of the oestrus cycle. The lowest GnRH induced LH response was found on 
Day 4 in control animals, but already on Day 2 in naltrexone treated animals. Together with 
the data on follicle maturation on Day 2 and surge like LH levels on Day 5 of 2 other 
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naltrexone treated gilts also suggests that the naltrexone treatment had advanced the timing of 
events during the follicular phase. The inhibitory actions of EOP's could be directly on the 
pituitary or indirectly through the GnRH pulse generator. Chao et al, (1986) found no effect 
of naloxone (added in vitro) on GnRH stimulated LH secretion from bovine pituitary cells, 
suggesting that EOP's do not modulate LH secretion at the level of the pituitary. In a previous 
study, we reported an advanced termination of the preovulatory LH surge after repeated ICV 
treatment with naltrexone during the follicular phase (Chapter VII), supporting a central site 
of action. This notion is in line with the results of studies in intact or E2B primed mature 
OVX gilts (Armstrong et al, 1988; Yearwood et al, 1991; Kraeling et al., 1992) and intact 
sheep (Currie et al, 1991), showing a delayed preovulatory LH surge after iv or ICV 
treatment with the opiate agonist morphine. Thus, one could speculate that EOP's exert an 
inhibitory action on the sequence of processes that lead to the preovulatory LH surge and that 
interruption of EOP activity permits generation of the surge. 
In summary, the results from the present pilot study suggest that responsivity of the pituitary 
to GnRH changes during the follicular phase, and that EOP's modulate the timing of events 
that eventually lead to the preovulatory LH surge by an inhibitory action at the suprapituitary 
level. 
Aknowledgement 
The authors like to thank the MSc students Hinke ten Hulscher and Regis Lamberts for their 
assistance in the development of the superfusion system. Furthermore we like to thank Corrie 
Oudenaarden for the analysis of the superfusion samples 
Chapter VI 
A new technique for implantation of a chronic 
cannula in the lateral brain ventricle of postpubertal, 
freely moving pigs 
J.A.J. Dierx and F.J.C.M. van Eerdenburg 
Department of Human and Animal Physiology, Wageningen Agricultural University, 
Haarweg 10, 6709 PJ Wageningen, The Netherlands. 
Department of Herd Health and Reproduction, Faculty of Veterinary Medicine, Utrecht 
University, Yalelaan 7, 3584 CL Utrecht, The Netherlands. 
New technique for implantation of chronic cannulas in the lateral ventricle 71 
Abstract 
Intracerebroventricular (ICV) cannulation in adolescent and adult pigs has some unique 
problems. Placement of the cannula is very difficult due to large individual variability in size 
and structure of the skull and frontal sinus. Furthermore, the rough behaviour of the animals 
makes it necessary to restrain the animal for ICV treatment, which is disadvantageous when 
studying responses to stress. In the present study, we developed and employed a cannulation 
system for pig brain, based on landmarks on the neurocranium, that enabled us to perform 
ICV treatment in freely moving post pubertal animals for a long period of time. Furthermore, 
plasma Cortisol concentrations have been determined in freely moving pigs treated ICV with 
a-CSF or naltrexone to validate the present ICV method for effectivity and stressfulness. 
Introduction 
Intracerebroventricular (ICV) cannulation has facilitated investigation of the role of 
neuropeptides in modulating pituitary function and measuring concentrations of 
neuropeptides and/or neurotransmitters in the cerebrospinal fluid (CSF) in the rat (Rivest et 
al, 1993; Bonavera et al, 1994), sheep (Conover et al, 1993) and primate (Meyers, 1977). A 
method for cannulation of the lateral ventricles in prepubertal pigs has been described by 
Poceta et al. (1981) and has been used with some modifications by Barb and co-workers in a 
number of studies (Barb et al, 1989; Estienne et al, 1990; Barb et al, 1991; Barb et al, 
1993). However, as reported by Poceta et al. (1981), ICV cannulation in the pig has some 
unique problems due to individual variability in skull structure and the absence of a detailed 
atlas of the brain with stereotactic co-ordinates. Furthermore, the development of the frontal 
sinus, the rough behaviour of pigs, including investigative activity, that could dislodge or 
damage the anchoring system, the difficulty of CSF-sampling or drug-injection in freely 
moving animals and the potentially dirtiness of the pig house, makes it very difficult to design 
a reliable and reproducible method of ICV-treatment in growing and freely moving pigs. 
The main purpose of this paper is to report a novel ICV cannulation technique for pigs which 
was developed utilising a stereotaxic apparatus affixed to the head and the injection device 
inserted into the frontal sinus. In addition, a pilot experiment was conducted to determine 
whether the injection method was stressful to the animal by measuring plasma Cortisol. 
Furthermore, plasma Cortisol response to ICV treatment with the opioid receptor antagonist 
naltrexone was used to validate the technique, since the opioid receptor antagonist naloxone 
has been shown to increase the plasma Cortisol concentration (Voklavka et al, 1979; Barb et 
al, 1986). 
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Materials and Methods 
Stereotactic Apparatus 
A stereotaxic apparatus (Figure 1, panel I, II, III) was developed that was attached to the head 
by means of a mouth piece at the front and two bone screws at the back of the skull. The 
apparatus was adjustable to every (adult) headsize. The base consists of two metal bars 
orientated in a medial-lateral direction (A) containing the attachment points to the head, 
connected by two parallel anterior-posterior sliding bars (B). By means of a tube-sliding 
mechanism over the two anterior-posterior bars, a micromanipulator unit (C) with a medial-
lateral orientation is attached to the base by two metal stands. Lateral movement of the 
micromanipulator can be made by a tube-sliding mechanism over two parallel bars, that can 
also be rotated 60°in total (30° to either side) in the vertical anterior-posterior plane. The 
micromanipulator unit itself was attached to the apparatus by means of an aluminium disc 
(Figure 1, panel II D and III D), that could be rotated 50° in total in the vertical medial-lateral 
plane. In both the anterior-posterior and medial-lateral direction, scales in millimetre were 
attached for measurement of cannula placement. 
ICV Injection Device 
The injection device (Figure 2 panel I, II, III) consisted of a stainless steel cup (A) with a luer 
lock cavity (B) of stainless steel ending in a stainless steel tube on the outside of the cup. The 
cup was closed by a Teflon® (PTFE=polytetrafluorethene) lid (C) that was locked with a 
bayonet catch. By fastening the socket cap screw (D), containing a Teflon lid, the orifice of 
the luer-lock cavity is closed and the bayonet catch is ultimately secured. This construction 
was wrapped in a Teflon hull (E) to reduce the noise when unlocking and to prevent an 
inflammatory reaction and skin overgrowth. 
A sterile flexible PVC tubing (Figure 3G) (PVC Perfusor® tubing, B. Braun Melsungen AG., 
Melsungen, Germany) was attached to the tip of the stainless steel luer-lock canula tube that 
connected the injection device to a stainless steel cannula designed for placement within the 
lateral ventricle (Figure 3 H). This cannula was kept in place by a perforated stainless steel 
collar that was fixed together with the cannula to the neurocranium using dental cement 
(Simplex Rapid®, Kendent Works, Purton Swindon, U.K.). 
Using this construction, growth and the further development of the frontal sinus does not 
affect the co-ordinates of the ICV cannula since the distance between neurocranium and the 
lateral ventricle remains constant (Table 1) during development around and after puberty, as 
was found in pigs of several crossbreeds and ages. An increase in the distance between the 
skull bone and neurocranium is compensated for by the flexible tubing. 
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Determination of cannula-placement and point of entry 
The exact caudal-ventral and lateral co-ordinates of the site of cannula-placement on the 
neurocranium were determined empirically in 17 saggitally and coronally cut heads of female 
pigs of the different crossbreeds and age from an abattoir. To determine caudal-ventral co-
ordinates, the distance between the neurocranium and the lateral ventricle in a perpendicular 
line on the neurocranium were measured (Table 1). In addition, the distance between the 
caudal bone rim and most frontal dip in the neurocranium (Table 1, A), i.e. the most frontal 
part of the brain, and the distance from the dip in the neurocranium to the lateral ventricle 
(Table 1, B) were determined using a sliding calliper, to calculate a multiplication factor (f = 
B/A; f = 0.55), which was used to determine the rostral-caudal co-ordinates (Figure 4 panel I 
and II). These co-ordinates were then measured from the anterior calliper point, i.e. the dip in 
the neurocranium. The point of entry was then determined at 5 mm lateral to the medial bone 
septum from this point; the drill was angled at 5° caudally. 
Accuracy of the calculated co-ordinates and the technique of cannulation was verified using 8 
heads of sows of different crossbreeds and age obtained from the abattoir by verification of 
placement with methylene blue. After injection of the dye, brains were removed and site of 
injection was determined. 
Intracerebroventricular cannulation of the lateral ventricle 
From three days before until three days after surgery, gilts (great Yorkshire x British 
Landrace; weight range 100-150 kg) were given 12 ml of the antibiotic Methoxasol-T® (20 
mg Trimethorprim/ml, 100 mg sulfamethoxasol/ml, AUV, Cuijk, The Netherlands) orally 
once a day. Animals were fasted overnight and approximately 45 minutes prior to surgery 
they were premedicated by i.m. administration of 6 mg azaperone kg'1 body weight 
(Stresnil ; Janssen Pharmaceutica BV, Tilburg, The Netherlands). During general 
anaesthesia, which was induced and maintained using a mixture of 02/N20, enflurane 
(Ethrane®, Abort, B.V., The Netherlands), heart rate and respiration were monitored. Surgery 
was carried out under standard sterile conditions and the animals underwent surgical 
procedures in the ventral recumbency. A circular piece of skin tissue, subcutis and underlying 
periosteum, 50 mm in diameter centered on the midline of the head, was excised. A piece of 
frontal-parietal bone 40 mm in diameter was excised using a circular sawblade (Figure 3 A) 
and the frontal sinus was exposed. The circular bone tissue and the remaining spongeous bone 
within the 40 mm perimeter were removed from the neurocranium using a chisel. The exact 
caudal-ventral and lateral co-ordinates of the site of cannula-placement on the neurocranium 
were determined as described earlier, using the dip in the neurocranium and the most caudal 
bone rim as landmarks (Figure 4 panel I and II). The stereotaxic apparatus was affixed to the 
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Figure 1. Stereotaxic apparatus. Frontal lateral side (I), caudal (II) view and illustrative drawing (III) of the 
stereotaxic apparatus with the base consisting of two medial-lateral bars (A) and two parallel anterior-
posterior bars (B). The micromanipulator is attached to a disk (D) that is mounted on a block (C) for medial-
lateral movement. 
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III 
Figure 2: The ICV injection device. The intact (I), the separate parts (II) and a schematic drawing of the 
device (III). The stainless steel cup (A) with the Liter lock mouthpiece (B). This is protected from the external 
environment by a Teflon9 lid (C), closed by a bayonet catch and secured by a socket cap screw (D). Inside the 
Teflon lid (C), a piece of rubber is mounted to securely close the Luer lock mouthpiece (B). The total 
construction is wrapped in a Teflon® hull (E). 
skull by means of a bit in the mouth and 2 bone screws at the back of the head (Figure 1 panel 
I, II, III).Three 2 mm diameter holes were drilled (Figure 3 B) in the neurocranium near the 
site of cannula placement, 2 mm in depth for placement of screws. A hole, 2 mm in diameter 
was drilled that penetrated the neurocranium at the chosen site for placement of the cannula. 
The dura mater was punctured carefully before lowering the cannula. The injection cannula 
was attached to a 250 mm long tube (Figure 3G; PVC Perfusor® tubing, B. Braun Melsungen 
AG., Melsungen, Germany) filled with 0.9% saline and vertically held above the guide tube. 
The cannula and PVC tube were led through a guide tube (Figure 3 C) and fixed with a screw 
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at the cannula-tube connection to assure rigidity between guide tube and injection cannula. 
This unit was attached to the stereotaxic apparatus. When the cannula, equipped with a 
perforated collar, was placed on the dura, the syringe with 0.9% saline was detached from the 
PVC tubing with the meniscus at the top of the tubing, approximately 150 mm above the 
guide tube. Subsequently, the cannula was slowly lowered stereotaxically by means of the 
guide tube until an influx of fluid was observed indicating entrance into ventricular space 
(Buxton, 1988). The perforated collar was fixed with dental cement (Simplex Rapid®, 
Kendent Works, Purton Swindon, U.K.) around the cannula on the neurocranium. The tube 
connected to the cannula was cut to a length of approximately 50 mm and connected to the 
tube connector (Figure 2 panel III and Figure 3 D) on the bottom of the cup, which fitted 
precisely in the 40 mm hole of the outer skull. Before attachment of the injection device to 
the skull with three vitallium screws (diameter 2.7 mm, length 20 mm, Instruvet, Amerongen, 
The Netherlands), 10 ml of the antibiotic Ritriprim® (per 9.5 g gel, 300 mg rifamycine and 
200 mg trimethoprim, Dopharma, Raamsdonksveer, The Netherlands) was injected into the 
frontal sinus in order to prevent infection. A silicone layer was placed between the skin and 
injection device. 
Cannulation of the jugular vein 
Gilts were fitted with a jugular vein catheter immediately after the ICV cannulation, as 
described by Janssens et al. (1994). An indwelling catheter (Silastic® Medical Grade Tubing, 
0.040 in. i.d., 0.085 in. o.d.; Dow Corning, Michigan U.S.A.) was implanted into the external 
jugular vein pointing towards the cranial vena cava. The catheter was passed s.c. and 
externalized between the scapulae. A one-way luer-lock stopcock (Vygon BV, Veenendaal, 
The Netherlands) was secured to the end of the catheter. The catheter was covered in a 
harness of 23 cm x 20 cm PVC/Nylon (Bizon Chemie, Goes, The Netherlands) that was fixed 
on the back of the animal by means of chest belts. 
The catheter was flushed with saline once a week and filled with heparinized saline (25 IU 
heparin/ml of 0.9% saline; Leo Pharmaceutical Products, The Netherlands) when not in use. 
When catheter patency was reduced, obstructions were removed as described by Leuvenink 
and Dierx (1997). In short, a solution of 25000 IU Kabikinase® (Kabi Pharmacia, Sweden), 
2500 IU heparin and 0.2 ml Ticarpen® (Beecham, England) was added to 25 ml sterile 25% 
polyvinylpropylene (PVP)/saline (Merck, Germany) solution. After 1 week the catheter was 
flushed with a 2% heparine/saline solution. 
ICV Injection Procedure 
Before injection, the lid was removed using an Allan wrench (Figure 3 E) to loosen the socket 
cap screw (Figure 2D) followed by the use of a bipointed wrench (Figure 3 F) inserted into 
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Figure 3: ICV surgery tools. Bone from the skull is excised with the circular sawblade (A) and the holes for 
the screws and cannula are drilled using a manual drill (B). With the guide tube (C), the cannula and 
perforated collar (H) are positioned and attached to a PVC tube (G), filled with 0.9% saline. After fixing the 
cannula, the tube is cut and attached to the tube connector (D) of the ICV injection device. The wrench (E) 
and bipointed wrench (F) are used to loosen the screw and the lid respectively. 
Figure 4: Positioning of the cannula. Skull model (I) and schematic drawing (II) of cannula positioning. The 
cannula was placed at the point 5 mm lateral to the medial bone septum. Dorsal-ventral position was 
determined by multiplying the distance from the front of the neurocranium to the most caudal bone rim by a 
factor of 0.55, which was then measured off from the anterior calliper point angling at 5° caudally. 
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semicircular grooves in the lid (Figure 2 III) to unlock the bayonet catch and extract the lid. 
This lid was kept in a 70% alcohol solution during the injection procedure. A piece of 1 meter 
long PVC tube (Perfusor® tubing, B. Braun Melsungen, Melsungen, Germany) with a luer 
lock stopcock two-way valve (Vygon BV, Veenendaal) containing a 1 mg naltrexone (Sigma 
Chemicals, St. Louis, U.S.A.) in 500 ul artificial cerebrospinal fluid (a-CSF, per liter 
solution: 166 mg CaCl2, 240 mg MgS04, 134 mg KC1, 170 mg KH2P04, 2,184 mg NaHC03 
and 7,247 mg NaCl, pH=7.6) was connected to the injection device with the luer-lock 
stopcock and the solution was injected followed by 500 ul of a-CSF to overcome the dead 
volume in the system. After injection, the lid was replaced and locked. 
Experimental Procedures 
As a pilot experiment, 7 crossbred gilts (Great Yorkshire x British Landrace; Pig 
Improvement Company, Oxfordshire, U.K.; weight range 100-150 kg) which had shown 2 or 
more oestrous cycles of 19 to 21 days were used to determine the effect of the ICV injection 
procedure on plasma Cortisol concentrations by ICV treatment with a-CSF or the EOP 
antagonist naltrexone. The gilts were housed in individual pens (approximately 6 m2) with a 
concrete floor that was covered with wood shavings, except for a slatted dunging area at the 
rear of the pens. Gilts were exposed to 12:12 light: dark cycle and ambient room temperature 
ranged from 15 °C to 25 °C. Pigs were fed at 8.00 h and 16.00 h 1 kg of a pelleted, dry sow 
feed (12.2 MJ of metabolizable energy per kilogram containing 15.4 % crude protein) and 
water was available ad libitum. Cannulation of the lateral ventricle and the jugular vein was 
performed, as described earlier. After a recovery period of 7 days, pigs were treated ICV with 
500 ul of a 2 mg/ml naltrexone solution (N=2) or 500 ul a-CSF (control; N=5). From 
naltrexone treated animals, blood samples were taken every 12 minutes for 1 hour before, 3, 
8, 14, 20 and 26 minutes after ICV treatment and every 12 minutes for 2 additional hours. 
From control animals, blood samples were taken every 12 minutes during 8 hours. Blood 
samples (approximately 5 ml) were collected in tubes containing 50 ul EDTA solution (144 
mg/ml of saline; Triplex®III, Merck Nederland, The Netherlands) to prevent clotting. 
Contents of the tubes were mixed and placed on ice, subsequently centrifuged at 3000 x g for 
15 minutes at 4 °C and stored at -20 °C until analysis for Cortisol using a specific 
radioimmunoassays (RIA's) as described by Janssens et al. (14). After 6 weeks, the naltrexone 
treated animals were killed to check cannula placement by cutting the heads saggitally and 
coronally. The experiments were approved by the Committee on Animal Care and Use of the 
Agricultural University, Wageningen, The Netherlands 
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Statistical Analysis 
For statistical analysis, the means of Cortisol concentration at 9:00 h (the hour before 
treatment) were compared to means of the Cortisol concentration of 13:00 h (the first hour 
after treatment). The effect of ICV treatment with naltrexone or a-CSF on plasma Cortisol 
concentrations was analysed using a two tailed student T-Test. 
Table 1: Data of distances between anatomical structures in pig skull 
Mean ± SEM 
Range 
Distances (in mm) between: 
NC - LV BR - DNC (A) DNC - LV (B) 
20.1 ±0.4 87 ±1.9 47 ±0.9 
18-22 70-102 41-56 
factor 
(f=B/A) 
0.55 ± 0.008 
0.51-0.62 
Data are presented as mean ± SEM and the range. Data were determined in 17 sows of 
different crossbreeds and age that were obtained from an abattoir. NC = neurocranium, LV : 
lateral ventricle, BR = most caudal bone rim, DNC = dip in neurocranium. 
Results 
Recovery 
Animals exhibited normal eating behaviour, which reappeared within 24 hours after surgery. 
The skin healed within 3-4 days with minor inflammation. One animal exhibited temporary 
paralysis of the left hindleg after surgery, due to the positioning of the leg during surgery. 
However, this had healed by 24 hours post surgery. Post mortem examination revealed that 
all animals had a fungal infection in the frontal sinus. However, none of the animals showed 
any behavioural or physical signs of discomfort. 
Solidity of the ICV injection device and cannula patency 
Although, the pigs frequently rubbed their heads during the first days post surgery, none of 
the ICV injection devices were dislodged or damaged by their rough behaviour. In addition, 
the ICV injection devices were not damaged or dislodged by the biting behaviour of 
neighbouring pigs. Furthermore, in the 5 animals that were not killed to check cannula 
placement, patency of ICV cannulae remained at least up to 6 months, as checked by 
flushing with a-CSF. 
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ICV naltrexone on plasma Cortisol 
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Figure 5. Plasma Cortisol concentrations in animals treated ICV with a-CSF or naltrexone. Top panel shows 
the profiles of the Cortisol concentrations of gilts (N=2) treated with ICV naltrexone injection relative to time 
of injection (t=0). Bottom panel presents data of plasma Cortisol concentrations at 9:00 h and 13:00 h of 
animals treated ICV with a-CSF (N=5) or naltrexone (N=2) at 11:00 h. 
* = significantly different (p<0.05) 
Cannula-placement 
The data obtained from the 17 sows showed that the distance from the dip in the 
neurocranium, i.e. the most rostral part of the brain, to the most caudal bone rim, respectively 
the lateral ventricle, showed no considerable individual variation (Table 1). In addition, no 
considerable individual variation was found in the distance from the neurocranium to the 
lateral ventricle when measured in a perpendicular line to the neurocranium (Table 1). 
The position and orientation of the cannula in the skull and cavity of the brain is shown in 
Figure 4 (panel I, II). After injection of the dye, methylene blue was found in the lateral 
ventricle of the brains of all 8 sows, with the point of entry of the cannula in the body of the 
lateral ventricle dorsally from the body of the caudate nucleus. In all animals of the pilot 
experiment it was found that, when entering ventricular space, an influx of a-CSF from the 
PVC tubing was observed and CSF could be aspirated. Post mortem check of cannula 
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placement in 2 gilts from the pilot experiment, showed the same point of entry as the sows 
that were injected with dye. In these pigs, it was found that the tip of the cannula had 
penetrated the corpus callosum, protruding in the ventricle over a length of 2 mm. 
Plasma Cortisol 
Pre-treatment Cortisol concentration was not different between a-CSF and naltrexone 
treatment (Figure 5 bottom panel). ICV treatment with a-CSF had no significant effect on 
plasma Cortisol concentration. ICV treatment with naltrexone increased plasma Cortisol 
concentration significantly compared to preferment Cortisol concentrations (Figure 5). Plasma 
Cortisol concentrations remained increased and were significantly higher (p<0.05) in 
naltrexone compared to control pigs at 3 hours post treatment (Figure 5 bottom panel). 
Discussion 
The ICV cannulation as described in the present study differs from the method used by 
others. First, in the method as presented in this study, the stereotaxic apparatus is placed on 
the skull without the use of ear bars. Therefore, there is no risk of damage to the eardrums. 
The use of ear bars has shown some adverse effects on the eardrums (Barb, personal 
communication). 
Second, the orientation for cannula placement takes place on the neurocranium instead of the 
frontal-parietal bone together with the interaural axis. There is considerable variation in skull 
structure between breeds of pig and individual pigs. As shown in the present study, the 
neurocranium has considerable variation with regard to rostral-caudal position and distance 
relative to the lateral ventricle. By computing factor f, this individual variation between 
animals and thereby variability in cannula placement is minimised. 
Third, in the present method, the cannula that is fixed on the neurocranium (inner table of the 
frontal-parietal bone) is connected by means of flexible PVC tubing to the injection device on 
the frontal-parietal bone, in contrast to methods used by others (Poceta et al, 1981; Barb et 
al, 1993), where the cannula is fixed directly on outer table of the frontal-parietal bone of the 
skull. When studying central mechanisms, during development, a problem may arise, since 
theouter table of the frontal-parietal bone shifts in a rostra-dorsal direction due to the 
development of the frontal sinus. This shift might pull the cannula out of the ventricle as has 
been reported by Poceta et al. (1981). By attaching the cannula to the neurocranium and 
connecting it to an injection device at the frontal-parietal bone with a flexible PVC tube, the 
outgrowth of the frontal sinus during growth of the animal does not affect the position of the 
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cannula. The present method opens the possibility to study maturation processes in the brains 
from the age of puberty until adulthood. 
Fourth, another difficulty in other methods for ICV cannulation and injection in pigs is the 
anchoring system. Due to the rough explorative behaviour of pigs it is difficult to maintain 
external cannulas in place. Furthermore, it is very difficult to maintain a sterile environment. 
By internalizing the site of injection in an injection device that is located in the frontal sinus, 
as described in this paper, the site is protected against dislodgement and damage. None of the 
implanted ICV injection devices were damaged or dislodged by the animal itself or 
neighbouring animals. In addition, by cleaning the injection site with alcohol prior to 
covering it with an alcohol sterilised Teflon lid, sterility is maintained. Although, all animals 
were treated with anti biotics, we could not prevent a fungal infection in the frontal sinus. 
However, none of the animals used in the pilot study, and only 1 out of 12 animals used in a 
following study (Chapter VII), showed an infection of the brain or meningitis. How fungal 
infection in the frontal sinus can be prevented in future studies, is currently under 
investigation and the use of an antiseptic drain or frequently flushing the frontal sinus with 
sterile saline and/or antibiotics could be considered. 
When studying mechanisms that are influenced by stress, it is important to minimise stress, 
such as restraining animals for ICV treatment. Using the injection device and an Infusor 
tubing as described in the present study, animals are not restrained for ICV treatment. Plasma 
Cortisol concentrations were not increased by ICV treatment with a-CSF, suggesting that 
animals are subjective to no or minimal stress using the present ICV technique. ICV treatment 
with 1 mg naltrexone increased plasma Cortisol concentrations. These findings support studies 
in pigs (Barb et al., 1986) and human (Voklavka et al., 1979), reporting increased plasma 
Cortisol concentrations preceded by increased ACTH release after treatment with naloxone. In 
view of the route of administration and the relatively low dose of naltrexone used (Barb et al, 
1989), it is likely that naltrexone exerted its action within the brain. Since the present study is 
only a preliminary experiment, further research is needed to substantiate this suggestion. 
In summary, the present study reports a modified ICV technique that enables ICV injection in 
freely moving, large, growing pigs. This technique should prove to be useful for studies 
during pubertal development, since this technique prevents dislodgement or damage of the 
anchoring system or the cannula growing out of the ventricle. Thus far we have been able to 
follow animals for a longer (6 month) period of time. 
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Abstract 
Endogenous opioid peptides (EOP's) have been shown to inhibit the pulsatile LH secretion 
during the luteal phase at the level of the hypothalamus. The involvement of EOP's in 
regulating pulsatile LH secretion during the E2fi dominated follicular phase was investigated 
by treating freely moving cyclic gilts intracerebroventricular twice daily for 6 days of with 1 
mg of the opioid receptor antagonist naltrexone (N=4) or a-CSF (N=5) after oestrus 
synchronisation with altrenogest. Blood samples were taken frequently (every 12 minutes 
during 8 hours) on Day 2, 4, 5 and 6, and every 6 hours on Days 1, 3 and from Day 6 
onwards. Pulse frequency, pulse amplitude and mean plasma concentration ofLH was lowest 
on Day 2 and 4 reaching highest values on Day 6 (the average day of the preovulatory LH 
surge and first day of oestrus). Mean LH concentration returned to baseline values after the 
preovulatory LH surge significantly sooner in naltrexone than control animals. Naltrexone 
had no effect on pulse frequency and mean LH concentration, whereas it increased pulse 
amplitude on Day 4. 
In summary, the results show that LH pulse frequency remains constant during the follicular 
phase, whereas LH pulse amplitude decreases from early to mid follicular phase, and increases 
from mid to late follicular phase. Both, LH pulse amplitude and pulse frequency, reach peak 
values at the day of the preovulatory LH surge. It is hypothesised that EOP's delay the timing of 
the preovulatory LH surge by decreasing pulse amplitude during the negative feedback phase 
ofE2fi in early and mid follicular phase. 
Introduction 
The role of endogenous opioid peptides (EOP) in the regulation of the pulsatile LH release has 
been investigated in a variety of species (Whisnant and Goodman, 1988, Kaynard et al., 1992; 
Chang et al., 1993; Heisler et al., 1993). Opioid receptor antagonists, like naloxone and 
naltrexone, are reported to increase the LH release (Muraki et al., 1979; Remorgida et al, 1990; 
Barb et al., 1992; Chang et al., 1993; Genazzani et al., 1993). The effect of these non selective 
opioid ligands, depends on the presence of gonadal steroids. During the progesterone dominated 
luteal phase, EOP's exert a tonic inhibition on plasma LH by decreasing LH pulse frequency and 
pulse amplitude as has been shown in rat (Higuchi and Kawakami, 1982), sheep (Montgomery et 
al. 1985), pig (Barb et al., 1988) and humans (Rossmanith et al., 1989). In the oestradiol (E2J3) 
dominated follicular phase, the involvement of EOP's in regulating pulsatile LH release is not 
clear. It seems that EOP's are not involved in the negative feedback of E2B on the pulse amplitude 
and mean plasma concentration of LH during the early follicular phase (Rossmanith et al., 1989; 
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Okrasa et al, 1992). However, during the late follicular phase and the presumed positive feedback 
of E213, increases of these parameters of LH release were found after systemic treatment with 
opioid receptor antagonists in humans (Rossmanith et al, 1989), rats (Piva et al, 1985) and pigs 
(Okrasa et al, 1992). In view of recent studies, the question arises whether EOP's act as an 
intermediate in the negative and/or positive feedback of oestradiol, or play a permissive role in the 
regulation of the pulsatile LH release in the generation and timing of the preovulatory LH surge 
(Massotto et al, 1990; Kraeling et al, 1992; Walsh and Clarke, 1996; Smith and Gallo, 1997). 
It is thought that opioids exert their possible inhibitory action on the pulsatile LH release mainly at 
the level of the hypothalamus. This opioidergic inhibition is highly associated with plasma 
concentration of progesterone during the luteal phase (Ferrer et al, 1997). Studies in sheep 
(Whisnant et al, 1991), rat (Kubo et al, 1983), primate (Pau et al, 1996), humans (Kawahara, 
1991) and pig (Asanovich et al, 1998) show that opioid receptor antagonists are able to increase 
pulse frequency, pulse amplitude and mean plasma concentration of LH by disinhibiting the 
GnRH pulse generator. However, whether EOP's play a role in the feedback effects of E2I3 during 
the follicular phase, and if so whether they have a central site of action, is still not known. 
The aim of the present study was to investigate whether EOP's in the brain are involved in the 
regulation of the pulsatile LH release on multiple days during the follicular phase of the oestrous 
cycle by treating freely moving intact gilts with repeated ICV injections of naltrexone. 
Materials and Methods 
Animals and housing 
The experiment was conducted with 12 crossbred gilts (Great Yorkshire x British Landrace; 
Pig improvement company, Oxfordshire, UK), which had shown 2 or more oestrous cycles of 
19 to 21 days. Upon arrival, the animals, weighing approximately 130 kg, were housed loose 
in individual pens (approximately 6 m ) with a concrete floor that was covered with wood 
shavings, except for a slatted dunging area at the rear end of the pens. The gilts were kept 
under 12:12 light: dark and ambient room temperature ranged from 15°C to 25°C, and fed 1 
kg of a pelleted, dry sow feed (12.2 MJ of metabolizable energy per kilogram containing 
15.4% crude protein) at 8:00 h and 16:00 h. Water was available ad libitum. 
Surgery 
All animals were fitted with an intracerebroventricular (ICV), and a jugular vein cannula as 
described by Dierx et al. (1998, submitted) and Janssens et al. (1994) respectively. In short, 
animals were given 12 ml of the antibiotic Methoxasol T® (20 mg Trimethorprim/ml, 100 mg 
sulfamethoxasol/ml, AUV, Cuijk, The Netherlands) orally once a day, from three days before 
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until three days after surgery. Animals were fasted overnight, and approximately 45 minutes 
prior to surgery they were premedicated by i.m. administration of 6 mg azaperone kg' body 
weight (Stresnil®; Janssen Pharmaceutica BV, Tilburg, The Netherlands). General anaesthesia 
was induced and maintained using enflurane (Ethrane , Abort BV, The Netherlands) and a 
mixture of 02/N20. The ICV cannula was implanted in the left lateral ventricle under 
guidance using a stereotactic apparatus that was attached to the head by means of a 
mouthpiece and a screw in the back of the head. The ICV cannula was connected, by means 
of a PVC tubing, to an injection device that was mounted in the skull. The luer-lock stopcock 
inside the device, the actual site of a-CSF or naltrexone injection, was covered by a lid. The 
jugular vein catheter (Silastic® Medical Grade Tubing, 0.040 in. i.d., 0.085 in. o.d.; Dow 
Corning, Michigan U.S.A.) was implanted into the external jugular vein with the tip pointing 
towards the superior vena cava. The catheter was passed s.c. and externalised between the 
scapulae. A one-way luer-lock stopcock (Vygon BV, Veenendaal, The Netherlands) was 
secured to the end of the catheter. The catheter was covered in a harness of 23 cm x 20 cm 
PVC/Nylon (Bizon Chemie, Goes, The Netherlands) that was fixed on the back of the animal 
by means of chest belts. The animals were allowed to recover from surgery for a minimum of 
7 days. Following surgery, animals were treated with the 10 cc of the analgesic finadyn twice 
daily for two days and with 10 cc of the antibiotic depocillin. 
The ICV cannula was flushed once during the recovery period with 500 ul sterile artificial 
cerebrospinal fluid (a-CSF, per liter solution: 166 mg CaCl2, 240 mg MgS04, 134 mg KC1, 
170 mg KH2P04, 2.15 g NaHC03 and 7.25 g NaCl, pH 7.6). The venous catheter was flushed 
once a week with sterile saline and filled with heparinized saline (25 IU heparin/ml of 0.9% 
saline; Leo Pharmaceutical Products, The Netherlands) when not in use. When catheter 
patency was reduced, obstructions were removed as described by Leuvenink and Dierx 
(1997). In short, a solution of 25000 IU Kabikinase® (Kabi Pharmacia, Sweden), 2500 IU 
heparin and 0.2 ml Ticarpen (Beecham, England) was added to 25 ml sterile 25% 
polyvinylpyrrolidone (PVP/saline, Merck, Germany) and injected in the catheter. After 24 
hours, the catheter was flushed with heparinized saline. 
Experimental design 
Before the experiment, the animals were handled daily for 3 weeks and habituated to the ICV 
injection and blood sampling procedures. After surgery and the recovery period, the oestrous 
cycles of all animals were synchronised by daily oral administration of 20 mg of the 
progesterone agonist altrenogest (Regumate^ in the morning feed for 21 days. The last day 
that animals received altrenogest treatment, was designated as Day 0. Starting on Day 1, 6 
animals received 1 mg naltrexone ICV twice a day at 8:00 h and 20:00 h for 6 days and 6 
animals received a-CSF (controls). On Day 2, 4, 5 and 6 after altrenogest withdrawal, 
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bloodsamples were taken every 12 minutes during 8 hours from 9.00 h until 17.00 h, 
according to the procedure described previously (Janssens et al, 1994). On Day 1, 3 and from 
Day 6 onwards, bloodsamples were taken every 6 hours until one day after first day of 
oestrus. Gilts that had not shown oestrous behaviour on Day 8, were scanned with ultrasound 
(Soede et al, 1990). Immediately after collection, the blood samples (approximately 5 ml) 
were transferred to ice cooled polypropylene tubes containing 50 ul EDTA solution (144 mg 
EDTA/ml of saline; Triplex®III, Merck Nederland BV,The Netherlands). The tubes were 
shaken and placed on ice and subsequently centrifuged at 3000 x g for 15 minutes at 4 °C. 
Plasma was collected and stored at -20 °C until hormone analysis. The experiments were 
approved by the Committee on Animals Care and Use of the Agricultural University, 
Wageningen, The Netherlands. 
Hormone analysis 
LH. Plasma samples were analysed for LH using a double antibody radioimmunoassay (RIA) 
as described by Niswender et al. (1970), using porcine LH (pLH iodination grade batch 
004/3; potency, 0.85 x NIH LH-S19; UCB bioproducts, Brussels, Belgium) as a standard and 
for radioiodination (specific activity, 38 uCi/ug). Anti-porcine LH batch 004 (UCB 
bioproducts, Brussels, Belgium) was used at a final dilution of 1:360,000, which gave an 
initial binding of the labeled hormone of approximately 39%. The minimal detectable 
concentration at the B/B0=0.9 was 0.1 ng/ml. The interassay coefficient of variation was 14.4 % 
and the intra-assay coefficient of variation was 7.2 %. 
Oestradiol. Plasma concentrations of oestradiol were measured in samples of 2.00 h, 8.00 h, 
14.00 h and 20.00 h on Day 1, 3 and 7, and in samples collected at 10.00 h, 12.00 h, 14.00 h and 
16.00 h on Day 2, 4, 5 and 6. After extraction of plasma with dichloromethane (DCM, Merck, 
Darmstadt, Germany), oestradiol concentration was determined using a single anti-body 
radioimmunoassay. For estimation of procedural losses, 500 cpm of [2,4,6,7-3H]E2 (NEN 
Chemicals, 's Hertogenbosch, The Netherlands) was added to 1 ml plasma sample and mixed with 
3 ml DCM. The organic phase of the mixture was evaporated under a stream of nitrogen and 
redissolved in 500 ul phosphate buffer with 1% BSA. An aliquot of 150 ul was taken to determine 
the recovery of [ HJEj . E2 concentrations were measured in duplicate (2 aliquots of 150 ul) using 
a specific rabbit antiserum against 6-keto-estrone (6-CMO-BSA). The antiserum was used in final 
dilution of 1:125,000. Oestradiol-1713 (Sigma Chemical Co., St. Louis, MO, U.S.A.) was used as a 
standard and [2,4,6,7-3H]E2 (specific activity 95.4 Ci/.mmol'1, NEN Chemicals, 's Hertogenbosch, 
The Netherlands) as a tracer. The main crossreacting steroids were oestrone (1.49%) and oestriol 
(0.21%). The minimal detectable dose at the 90% B/B0 level was 8 pg.ml"1. The intra- and inter-
assay coefficients of variation were 12.4 % and 17.4 % respectively. The amount of E2 was 
expressed in pg.ml"1 after correction for procedural losses, and daily means were calculated. 
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Detection ofoestrous 
Oestrus detection was performed by a back-pressure test in the presence of a vasectomized 
boar once daily in the morning on all days after withdrawal of altrenogest treatment. The time 
of oestrous was defined as the first day the sow showed a standing response. 
Pulse detection 
The profiles of LH release were analysed using the pulse analysis program of Maxima/Chromcard 
(Fisons Instrumentsjnterscience, Breda, The Netherlands) with baseline calculated according to an 
algorithm taken into account the total profile. A pulse was defined by a baseline-peak ratio of 0.5 
or lower and a minimal area under the curve of 50ng.ml" .min. The highest value of a pulse above 
baseline was taken as pulse amplitude. 
Statistical analysis 
Data of pulse frequency, pulse amplitude and mean plasma LH concentration, time of return 
to baseline levels after the preovulatory LH surge and the time of oestrus, were analysed 
using SAS statistical analysis system (1990). The effect of naltrexone on these parameters 
was tested using the GLM procedure by means of a F-test to analyse the linear model: Y{j =u 
+ Tj +eu+ Dj +(TxD)jj +e2;j; Where Yy = value of parameter in a gilt (n=l 1) receiving 
treatment i on sampling day j ; u = overall mean; T~ fixed effect of treatment i (1,2); e ^ 
error term 1, which represents the random effect within treatment i; Dj= fixed effect of 
sampling day j (1,.,4); e2ij= error term 2, which represents the random effect of treatment i 
between sampling days j . The effect of naltrexone treatment was tested against error term 1. 
The other effects were tested against error term 2. Differences were considered significant 
when P<0.05. The parameters pulse amplitude, time of return to baseline levels after the 
preovulatory LH surge and the time of oestrus had no normal distribution and were therefore 
analysed with a Kruskal-Wallis test using the procedure Nparlway of the statistical analysis 
system SAS (1990). 
Results 
General 
During the experiment, 1 control and 1 naltrexone treated animal died of meningitis and of 
intestinal torsion respectively. In addition, 1 naltrexone treated animal showed neither 
oestrous behaviour nor a preovulatory LH surge. The data of this animal were excluded from 
analysis, since no ovarian follicles were detected when scanned with ultrasound. Furthermore, 
1 control animal had a silent oestrus, showing a preovulatory LH surge but no oestrous 
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behaviour. All other animals had the first day of oestrus on day 6 after termination of the 
altrenogest treatment. 
The preovulatory LH surge 
Five control and 4 naltrexone treated animals showed a preovulatory LH surge. In all cases, 
return of LH to baseline levels after the preovulatory surge could be accurately detected. In 
the naltrexone group LH returned to baseline values on average at 138 ± 4.9 h (N=4) after 
termination of the altrenogest treatment, which was significantly (P=0.01) sooner than in 
animals in the control group that reached baseline values on average at 166 ± 6.2 h (N=5) 
after altrenogest withdrawal. 
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Day after termination of altrenogest treatment 
Figure 1: Data represent mean ± SEM of LH pulse frequency (A; number per 8 h), pulse amplitude (B; ng/ml) 
and mean LH concentration (C; ng/ml) in control (closed bars; n=5) and naltrexone (open bars; n=4) treated 
animals during the follicular phase of the oestrous cycle. 
Time effects: 
* = significantly different from Day 4 (P<0.05). 
** = significantly different from Day 2 and 4 (P<0.05). 
***= significantly different from Day 2, 4 and 5 (P<0.05). 
Treatment effects: 
f = significantly different between a-CSF and naltrexone treatment (P<0.05). 
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Pulsatile LH release 
Data on plasma LH concentrations are presented in Table 1. No treatment effects were found 
in LH pulse frequency (P=0.08) and mean LH concentration (P=0.18) on Days 2, 4, 5 and 6 
after discontinuation of altrenogest treatment. LH pulse amplitude was significantly (P<0.05) 
higher in the naltrexone treated group compared to the control group on Day 4. 
An effect of time was found in LH pulse frequency (P=0.03), pulse amplitude (P=0.0004) and 
mean LH concentration (P=0.0025). LH pulse frequency was significantly higher on Day 6 
than on Day 2 and Day 4 (P<0.05). LH pulse amplitude was increased on Day 6 compared to 
Days 2, 4 and 5, and LH pulse amplitude was higher on Days 2 and 5 than on Day 4 
(PO.05). Mean LH concentration was significantly increased on Day 6 compared to Day 2,4 
and 5 (P<0.05) with a significantly higher mean LH concentration on Day 5 than on Day 4 
(P<0.05). 
Oestradiol 
Data on daily mean oestradiol concentrations are presented in Table 2. Plasma concentrations 
of oestradiol were not significantly affected by naltrexone treatment (P=0.33), but a time-
effect was found (P=0.0003). Mean oestradiol concentrations were higher on Day 5 than on 
Day 2, 4 and 6, with Day 4 showing higher mean oestradiol concentrations compared to Day 
2and6(P<0.05). 
Table 2: Mean oestradiol concentration on Day 2, 4, 5 and 6 after altrenogest withdrawal, 
day after altrenogest 
2s 
4b 
5C 
6a 
Data represent mean ± SEMofmean oestradiol concentration (pg/ml) in control (n-5) and naltrexone (n-4) 
treated groups of animals during the follicular phase of the oestrous cycle. Different superscript letters (a,b,c) 
in a column represent significant differences (P<0.05) in time. 
Discussion 
In the present study, repeated ICV treatment of pigs with the opioid receptor antagonist 
naltrexone was used to investigate the involvement of endogenous opioid activity in the brain 
in the regulation of LH release during the follicular phase in ovary-intact gilts. In naltrexone 
treated animals, plasma LH concentrations returned to basal significantly earlier after the 
preovulatory LH surge than in a-CSF treated controls. In view of the route of administration 
control (n=5) 
7.6 ± 3.5 
38 ± 8.6 
67 ± 5.8 
38 ±21 
naltrexone (n=4) 
13 ± 2.0 
46 ± 7.5 
64 ± 13 
6.6 ±4.5 
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and the relatively low dose of naltrexone used (Barb et al, 1989), it is likely that naltrexone 
exerted its action within the brain. Thus the data strongly suggest that activation of opioid 
receptors in the brain by EOP's participates in the regulation of the preovulatory LH surge in 
Pigs-
It remains unclear whether the premature cessation of the LH surge in the naltrexone treated 
gilts reflected a time-shift of the peak LH value or the complete surge (including onset), or 
was the result of an effect on the height of the surge or even on LH clearance kinetics, since 
the design of our study did not allow exact determination of these parameters. There is ample 
evidence from studies with rats (Allen and Kalra, 1986; Berglund et al, 1988), sheep (Currie 
et al, 1991) and humans (Snowden et al, 1984), however, indicating that tonic inhibitory 
activity of brain opioid systems precludes the occurrence of a LH surge during the late 
follicular phase, and that cessation of this inhibitory activity permits a surge to occur (Barkan 
et al, (1983; Okrasa et al, 1992; Roozendaal et al, 1997). A similar involvement of EOP's 
in the regulation of surge timing in pigs, is supported by data from Armstrong et al. (1988) 
who found that chronic administration of morphine (sc) to sows for 5 days after weaning 
delayed the onset of oestrus, and data from others (Yearwood et al., 1991; Kraeling et al., 
1992a) who reported a delayed preovulatory LH surge in E2B primed OVX gilts after IV or 
ICV morphine treatment with no effect on the height of the surge. 
The frequency and amplitude of LH pulses and mean LH concentration during the follicular 
phase showed significant time effects. LH pulse amplitude and mean LH concentration 
initially decreased to lowest values on Day 4 after termination of altrenogest treatment, and 
thereafter gradually increased during the late follicular phase. All LH parameters of study 
were highest on Day 6, which for most of the animals was the first day of oestrus and 
preovulatory LH surge. These dynamics of LH during the follicular phase may be explained 
from the plasma concentration of E2B. E213 increases during early follicular phase and exerts 
a "negative feedback" on pulse amplitude and therefore on mean LH plasma concentration. 
During the late follicular phase, E2B reaches peak values on the day before the preovulatory 
LH surge, positively influencing LH pulse amplitude and mean plasma LH concentration 
(Helmond et al, 1986; Kesner et al, 1989; Messinis et al, 1992; Matt et al, 1993). 
Naltrexone treatment in the present study had no effect on LH pulse frequency and mean LH 
concentration during the follicular phase of the oestrous cycle, but enhanced the pulse 
amplitude on Day 4 yielding values on that day that were comparable to those on Day 5 in 
control animals. It could thus be that the negative feedback of E2B influences the LH pulse 
amplitude, leaving pulse frequency unaffected. In line with this, studies in sheep (Whisnant 
and Goodman, 1988; Whisnant et al, 1991) reported that only pulse amplitude was increased 
by treatment with an opioid receptor antagonist during the high E2B levels of the follicular 
phase. From this, together with the abovementioned earlier return of LH to basal 
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concentrations after the preovulatory surge, we hypothesise that EOP's in the brain are 
involved in the timing of the preovulatory LH surge by decreasing LH pulse amplitude during 
the negative feedback of E2B. 
In summary, the results show that LH pulse frequency remains constant during the follicular 
phase, whereas LH pulse amplitude decreases when going from early to mid follicular phase and 
increase when going from mid to late follicular phase. Both, LH pulse amplitude and pulse 
frequency, reach peak values at the day of the preovulatory LH surge. Furthermore, the data 
suggest that EOP's delay the timing of the preovulatory LH surge possibly by decreasing LH pulse 
amplitude during the negative feedback phase of E2J3 in the early and mid follicular phase. 
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SUMMARY AND GENERAL DISCUSSION 
LH secretion during the oestrous or menstrual cycle, and the luteal phase in particular, has been 
studied in a variety of species as sheep (Whisnant et al, 1991), human (Fillicori et al, 1986; 
Rossmanith et al., 1990), pig (Okrasa and Tilton, 1992) and primate (Norman et al., 1994). During 
the luteal phase, plasma LH concentration has been shown to be decreased by endogenous opioid 
peptides (EOP's), mediating the negative feedback of progesterone (P; Yang et al., 1988; Barb, et 
al., 1992; Kaynard et al, 1992). Yet, relatively few data have been available on the pattern of 
pulsatile LH release during the oestradiol (E2B) dominated follicular phase of the oestrous or 
menstrual cycle, and whether EOP's also play an inhibitory role in LH secretion and/or the timing 
of events leading to the preovulatory LH surge and oestrus. 
In the present thesis, we have first described the pulse pattern of LH secretion during multiple days 
of the follicular phase of the oestrous cycle using the female tethered housed pig as a model. 
Second, we have demonstrated that EOP's seem to be involved in the timing of events leading to 
the preovulatory LH surge, but not in the regulation of the pulse pattern. Therefore, in this chapter, 
these processes will be described separately and possible functional implications of EOP's in the 
regulation of female reproduction are discussed. 
Stress and the Preovulatory LH Surge 
In Chapter II and IV, the tethered pig was used as an animal model to study the effects of 
chronic stress on the HPG-axis. This model was chosen because tethered housing leads to 
changes in neuroendocrine regulation and behaviour in which altered activity of endogenous 
opioids in the brain is an important feature (Cronin, 1985; Schouten and Wiepkema, 1991; 
Janssens et al., 1995b; Zanella et al, 1996; Loyens, Schouten and Wiegant, unpublished 
observations). It was found that the preovulatory LH surge and the expression of oestrus were 
delayed when long-term tethered pigs were released from their tether (Chapter II). This delay 
was likely not caused by loose or tethered housing per se, but rather by the change in housing 
condition that apparently represented a major challenge for the animals. One may speculate 
that such changes in reproductive parameters may occur independent of the exact nature of 
the stimulus and can be relevant for reproductive performance in pig breeding. Indeed, there 
is ample evidence that tethered housing renders the animals more reactive to environmental 
stimuli, although to a certain extend pigs can adapt to the chronic stress of tethered housing 
(Janssens et al, 1995b). In Chapter IV, no differences were found between long-term (6 
month) tethered housed pigs and loose housed controls regarding the onset of oestrus, 
possibly because animals had adapted to the tethered housing condition, which has been 
shown to occur within a few months after start of tethered housing (Janssens et al, 1995a). 
Previous reports indicate that in long-term tethered housed ("stress-adapted") pigs the activity 
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of EOP's is increased (Cronin, 1985; Schouten et al, 1991, Zanella et al, 1996). Although, 
oral treatment with the opioid receptor antagonist naltrexone led to a shift in the onset of 
oestrus, and possibly also of the preovulatory LH surge, we found no evidence for differential 
EOP activity in the regulation of reproductive processes between tethered and control pigs. It 
should be kept in mind, however, that our pigs had been tethered for more than 5 months, and 
the adaptive increase in EOP-activity may cease to be functional after several months 
(Janssens et al, 1995a). An interesting observation was the large variation in onset of oestrus 
in the naltrexone treated group of pigs. The individual variability in the response to 
naltrexone, described in Chapter III, may be relevant in this respect. 
Opioidergic Regulation of the Preovulatory LH Surge 
The data from Chapter II and IV suggested a possible role of stress and EOP's in the timing of 
the preovulatory LH surge and the onset of oestrus. Whether EOP's exert their actions at the 
level of the pituitary or the hypothalamus, or both, was investigated in Chapters V and VII. In 
a pilot study, described in Chapter V, we obtained data suggesting that the pituitary 
responsivity to GnRH, as assessed in vitro, changes during the follicular phase. Maximal 
responsivity was found around the day of the preovulatory LH surge. It was concluded that 
treatment with naltrexone seemed to advance the maximal pituitary responsivity and the 
preovulatory LH surge. To investigate whether EOP's might act at the level of the 
hypothalamus, a new intracerebroventricular (ICV) injection technique was developed as 
described in Chapter VI. Using this technique, we showed in Chapter VII that the 
preovulatory LH surge was terminated sooner after ICV treatment with naltrexone. Together 
with data on pulse amplitude, showing higher values after ICV naltrexone treatment on Day 4 
after termination of altrenogest treatment, this observation supports the hypothesis that EOP's 
delay the timing of events leading to the preovulatory LH surge, most likely at the 
hypothalamic level. This would be in line with studies by Armstrong et al. (1988), who 
reported that chronic administration of morphine (sc) to sows for 5 days after weaning 
delayed the onset of oestrus and studies by Yearwood et al. (1991) and Kraeling et al. (1992) 
showing a delay of the preovulatory LH surge in E2B primed OVX gilts after iv and ICV 
morphine treatment. 
The Role of EOP's in the Pulsatile LH Secretion during the Follicular Phase 
In Chapters IV and VII it is shown that the early follicular phase (approximately Days 1 and 2) is 
characterised by highly frequent, low amplitude LH pulses, followed by a decrease in pulse 
frequency during mid-follicular phase (approximately Days 3-5), and that the late follicular phase 
with the preovulatory LH surge (approximately Days 6-7) is constituted of pulses of high 
frequency and high amplitude. In addition, pituitary responsivity to GnRH appeared to change 
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during the follicular phase with maximal responsivity on the day of the preovulatory LH surge 
(Chapter V). These dynamics of LH during the follicular phase and pituitary responsivity are 
similar to those found in humans, primates and rats (Clayton et ah, 1980; Kesner et ah, 1989; 
Genazzani et ah, 1992; Rossmanith, 1995) and may largely be explained from the plasma 
concentration of E2I3. E213 starts to increases during early follicular phase, when it exerts a 
"negative feedback" on pulse amplitude and mean LH plasma concentration but enhances 
pituitary sensitivity for GnRH (Drouva et ah, 1983; Koiter et ah, 1987). Peak levels of E2B 
are reached at the end of the mid-follicular phase, when LH pulse amplitude and mean plasma 
concentration are positively influenced (Helmond et ah, 1986; Kesner et ah, 1989; Messinis et 
ah, 1992; Mattel ah, 1993). 
As found in Chapters IV and VII, the pulse pattern of LH during the follicular phase did not seem 
to be affected by EOP's, supporting other studies in humans (Genazzani and Petraglia, 1989; 
Genazzani et ah, 1993; Cagnacci et ah, 1995) and sheep (Currie et ah, 1992). Although naltrexone 
treated animals had higher LH pulse amplitudes than control animals on only 1 day of the 
follicular phase (Day 5 in Chapter IV and Day 4 in Chapter VII) this difference was no longer 
present when data were synchronised on the first day of oestrus (Chapter TV). Therefore, it was 
suggested that naltrexone did not change the dynamics of the LH secretion during the follicular 
phase but affects the timing of the preovulatory LH surge. The results from the pilot study in vitro 
(Chapter V) support this notion, as the pattern of pituitary responsivity to GnRH and plasma 
concentration of LH during the follicular phase seems to be shifted by naltrexone treatment. Thus, 
in contrast to the luteal phase where pulse frequency, pulse amplitude and mean plasma 
concentration of LH are inhibited by EOP's (Barb et ah, 1986; Genazzani et ah, 1993; 
Rossmanith, 1995), this is not the case during the follicular phase. 
Putative Mechanism for Opioid Modulation during the Follicular Phase 
The data presented indicate that EOP's do not only play an inhibitory role on the LH secretion 
during the luteal phase, but are also involved in the timing of the preovulatory LH surge in the pig. 
From Chapter II it might be suggested that, during the transition from the luteal to the follicular 
phase, P decreases rapidly, thus reducing EOP activity and leaving the GnRH pulse generator "free 
running". This results in an increased LH pulse frequency during the early follicular phase 
compared to the luteal phase as was found in humans by Rossmanith (1992) and Genazzani et ah 
(1993). Furthermore, P has been shown to exert a negative feedback on the LH secretion through 
EOP activation (Yang et ah, 1988; Barb, et ah, 1992; Kaynard et ah, 1992) by reducing pulse 
frequency of the GnRH pulse generator (Bouchard et ah, 1988; Couzinet and Schaison, 1993). 
Treatment with an opioid antagonist (Chapter IV and VII) pharmacologically accelerates the 
decline in EOP tone caused by decreasing plasma P concentrations, thus advancing the start of LH 
dynamics associated with the follicular phase. 
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During the mid-follicular phase, E2B secretion starts to increase (Chapter IV and VII; Bouchard et 
al, 1988; Genazzani et al, 1992) due to maturing follicles. The increase in circulating E2I3 
subsequently decreases LH pulse amplitude during the mid-follicular phase by inhibiting the 
GnRH pulse generator (Chapter IV, V, VII). Since E2B has been shown to stimulate EOP release 
in the hypothalamus (Frautschky and Sarkar, 1995) and to decrease electrical activity of the GnRH 
pulse generator (Kesner et al, 1987), it could be hypothesised that E2B acts through an opioid 
mechanism at the level of the hypothalamus. In addition, E2B increases the transcription of 
gonadotropin subunits but inhibits the secretion of LH (March et al, 1981; Knobil and Hotchkiss, 
1988), thus loading the pituitary with LH. Moreover, E2B has been reported to increase the 
number of GnRH receptors on pituitary gonadotrophs (Clayton and Catt, 1981; March et al, 1981; 
Bouchard et al, 1988), and thereby the responsivity of the pituitary to GnRH (Drouin et al, 1976; 
Kamel and Krey, 1982). When plasma concentrations of E2B start to decrease in the late follicular 
phase, EOP activity and thereby the "EOP-clamp" on the GnRH pulse generator and the "E2B-
block" of the LH release at the level of the pituitary might be reduced. Thereby, LH pulse 
frequency and pulse amplitude would be increased and the preovulatory LH surge would be 
permitted to occur. Indeed, blocking opioid receptors with an opioid antagonist advances the 
preovulatory LH surge (Chapter IV and VII). However, further research is needed to prove 
the validity of this model and to further elucidate the neuroendocrine processes that contribute 
to succesful reproduction. 
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Inleiding 
Het doel van dit proefschrift is meer inzicht te krijgen in de neuro-endocriene regulatie van 
het voortplantingshormoon luteiniserend hormoon uit de hypofyse tijdens de folliculaire fase 
van de oestrische cyclus van het vrouwelijk varken. In het bijzonder is bestudeerd of stress en 
endogene opioi'de peptiden dit systeem bei'nvloeden, en zo ja hoe deze factoren dat doen. 
Alvorens in te gaan op de experimenten en de resultaten, is het noodzakelijk om kennis te 
hebben van een aantal vaak terugkerende begrippen. 
De Hypothalamus-Hypofyse-Gonade As 
Het vermogen zich voort te planten wordt voor een belangrijk deel bepaald door de 
aanwezigheid van de voortplantingsorganen die de zogenaamde hypothalamus-hypofyse-
gonade (HHG) as vormen. De zenuwcellen ofneuronen in het hersengebied "de 
hypothalamus", geven het gonadotropine releasing hormoon (GnRH) af aan de portale 
bloedvaten die naar de hypofyse leiden. Dit GnRH stimuleert in de gonadotrope cellen van de 
hypofyse de vorming en afgifte van de gonadotrofines: het luteiniserend hormoon (LH) en het 
follikel stimulerend hormoon (FSH). Deze gonadotrofines stimuleren in de geslachtsklieren of 
gonaden de vorming en afgifte van de steroide hormonen testosteron, oestrogenen (E2B) en 
progesteron (P) respectievelijk in het mannelijk dier en vrouwelijk dier. Verder stimuleren ze 
de ontwikkeling van geslachtscellen en, in het vrouwelijk dier, de eisprong ofovulatie. De 
steroid hormonen koppelen op hun beurt direct of indirect terug (feedback) op de afgifte van 
GnRH in de hypothalamus en op de gonadotrope cellen van de hypofyse. In dit proefschrift is 
alleen aandacht besteed aan de hormonale regulatie in het vrouwelijk individu zodat de 
verdere beschrijving van de LH secretie alleen gericht is op het vrouwelijke individu. 
De Oestrische ofMenstruele Cyclus 
De hormonale profielen vertonen periodieke veranderingen, en worden de zogenaamde 
menstruele (in de mens en de niet-menselijke primaat) of oestrische cycli (andere zoogdieren) 
genoemd. Tijdens zo'n cyclus kunnen grofweg 2 fasen worden onderscheiden. De luteale of 
secretoire fase is de tijdsperiode die ligt tussen het moment van ovulatie en de menstruele 
bloeding. De tijdsperiode tussen het einde van de menstruele bloeding tot het moment van 
ovulatie wordt de folliculaire of proliferate fase genoemd. 
De hormonen GnRH, LH en FSH worden afgegeven in de vorm van regelmatige pulsen. Dit 
pulsatiel patroon is essentieel voor een goede regulatie van allerlei gebeurtenissen die de 
vrouwelijke vruchtbaarheid voor een groot deel bepalen. Tijdens de luteale fase zorgt een 
hoge P concentratie in het bloed voor een lage puis frequentie maar hogepuls amplitude van 
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LH door de GnRH-neuronen te remmen. Tijdens de vroeg-folliculaire fase daalt de P 
concentratie en neemt de LH puis frequentie toe terwijl de LH puis amplitude afneemt. 
Tijdens de folliculaire fase stijgt de E2J3 concentratie in het bloed die ervoor zorgt dat de puis 
frequentie van GnRH, en daardoor ook van LH, weer afneemt tijdens de mid-folliculaire fase 
("negatieve feedback"). Tijdens de laat folliculaire fase heeft E213 een "positieve feedback" 
die voor een kortstondig verhoogde afgifte van GnRH en vervolgens ook van LH zorgt. Door 
deze LH-piek wordt in het ovarium de ovulatie gestart, reden waarom deze hormoonpiek de 
preovulatoire LH piek wordt genoemd. 
Stress en Voortplanting 
Stress is een alomtegenwoordig verschijnsel in het leven en de reactie (respons) op stress 
wordt omschreven als "...een niet-specifieke reactie van het lichaam op een willekeurige 
stimulus (meestal schadelijk) die een verandering in het interne evenwicht veroorzaakt". 
Hoewel stress en de respons op stressvolle gebeurtenissen een belangrijke rol spelen bij de 
overleving van een individu, kan het ook een gevaar voor het welzijn en de gezondheid van 
het individu zijn. Ook de voortplanting wordt door stress beinvloed. Dit kan op meerdere 
manieren gebeuren. In het algemeen leidt stress tot een onderdrukking van de processen die 
bijdragen aan de voortplanting, vermoedelijk om energie te sparen voor processen die voor de 
overleving van het individu zorgen. In de moderne intensieve varkensfokkerij, waar de dieren 
veelal aangebonden in nauwe, individuele boxen worden gehuisvest en er daardoor sprake is 
van chronische stress, treedt er aanzienlijke uitval van dieren op mede door gereduceerde 
vruchtbaarheid en zelfs onvruchtbaarheid. Welke mechanismen hierbij een rol spelen is 
vooralsnog niet duidelijk. Gedacht wordt onder andere aan een langdurig verhoogde activiteit 
van endogene opioi'de peptiden, die betrokken zijn bij de respons op stress. 
Opioiderge Controle van de Gonadotrofine Afgifte tijdens de Oestrische Cyclus 
De expressie van endogene opioi'de peptiden (EOP) speelt een centrale rol in de negatieve 
feedback van steroid gonadale hormonen tijdens de oestrische cyclus. De opioi'de activiteit 
verandert met de veranderde concentratie van ovariele steroi'den tijdens de cyclus. Tijdens de 
P-gedomineerde luteale fase remmen EOP de LH puis frequentie continu waardoor de LH 
concentratie in het bloed laag blijft. Of EOP ook betrokken zijn bij de feedback door E2B 
tijdens de folliculaire fase is vooralsnog onduidelijk. Gegevens uit de literatuur wijzen erop 
dat EOP's niet betrokken zijn bij de negatieve feedback van E2I3 tijdens de vroeg- en mid-
folliculaire fase. Echter bij de "positieve feedback" tijdens de laat-folliculaire fase lijken 
EOP's een remmende invloed te hebben op de LH-afgifte. Verder lijken EOP's betrokken te 
zijn bij de timing en het optreden van de preovulatoire LH piek. 
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Dit Proefschrift 
In dit proefschrift is ten eerste het patroon van de pulsatiele LH afgifte tijdens meerdere 
dagen van de folliculaire fase van de oestrische cyclus beschreven, waarbij het aangebonden 
vrouwelijke varken als modelsysteem werd gebruikt. Ten tweede hebben we onderzocht of 
EOP's betrokken zijn bij de regulatie van het patroon van de pulsatiele LH afgifte en/of bij 
de timing en het optreden van de preovulatoire LH piek. Hoofdstuk I geeft een korte 
beschrijving van de reproductieve as, de betrokken organen, de hormonale regulatie en de 
interactie tussen de verschillende hormonen die leiden tot de oestrische of menstruele cyclus. 
Wanneer dieren die langduring aangebonden gehuisvest zijn geweest worden vrijgelaten, 
worden de preovulatoire LH piek en het moment van oestrus wordt vervroegd (Hoofdstuk II). 
Deze vervroeging wordt waarschijnlijk niet veroorzaakt door aangebonden of vrije 
huisvesting als zodanig maar meer door de verandering in huisvesting. Die verandering is 
waarschijnlijk een belangrijke prikkel. Immers, in Hoofdstuk IV werd er geen verschil 
gevonden in het moment van oestrus tussen langdurig (6 maanden) aangebonden varkens en 
vrij gehjuisveste controle varkens. Dat wijst erop, dat de aangebonden dieren waren 
geadapteerd aan hun huisvestingsconditie. Hoewel in dit Hoofdstuk de toediening van de 
opioid receptor antagonist naltrexon leidde tot een verschuiving van het moment van oestrus, 
en mogelijk ook de preovulatoire LH piek, hebben we geen bewijs gevonden voor een 
verschil tussen aangebonden en vrije dieren in de betrokkenheid van EOP bij de regulatie van 
de reproductieve processen. Een interessante waarneming was de grote variabiliteit in het 
moment van oestrus in de met naltrexon behandelde varkens. Die zou, gegeven de 
bevindingen in Hoofdstuk III, verklaard kunnen worden door een aanzienlijke individuele 
variabiliteit in de respons op naltrexon. 
Deze resultaten suggereren een mogelijke betrokkenheid van stress en EOP's bij de timing 
van de preovulatoire LH piek en het moment van oestrus. Of EOP aangrijpen op het niveau 
van de hypothalamus en/of de hypofyse is onderzocht in de Hoofdstukken V en VII. De 
maximale responsiviteit van de hypofyse voor GnRH wordt bereikt op de dag van de 
preovulatoire LH piek en dit moment van maximale responsiviteit lijkt, samen met de 
preovulatoire LH piek, door behandeling met naltrexon vervroegd te worden (Hoofdstuk V). 
Om de mogelijke effecten van naltrexon op het niveau van de hypothalamus in vivo te kunnen 
bestuderen, hebben we een nieuwe methode ontwikkeld die het mogelijk maakt om bij 
varkens farmaca direct in de laterale ventrikel van de hersenen te kunnen injiceren 
(Hoofdstuk VI). Met behulp van deze methode hebben we aangetoond dat injecties van 
naltrexon in de laterale ventrikel gedurende de folliculaire fase een vervroegd einde van de 
preovulatoire LH piek veroorzaakten. Samen met de hogere puis amplitude die tijdens de 
midfolliculaire fase (Dag 4) bij naltrexon behandelde dieren werd gevonden, ondersteunt dit 
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de hypothese dat EOP activiteit in de hersenen, waarschijnlijk op het niveau van de 
hypothalamus, het te vroeg optreden van de preovulatoire LH piek voorkomt. 
Het patroon van de pulsatiele afgifte van LH bestaat uit hoog-frequente pulsen met een lage 
amplitude tijdens de vroeg-folliculaire fase (ongeveer Dag 1 en 2). Tijdens de mid-folliculaire 
fase (ongeveer Dag 3-5) daalt de LH pulsfrequentie, terwijl de laat-folliculaire fase met de 
preovulatoire LH piek (ongeveer Dag 6-7) wordt gekenmerkt door hoog-frequente pulsen met 
een hoge amplitude (Hoofdstuk IV en VII). De responsiviteit van de hypofyse voor GnRH 
verandert gedurende de folliculaire fase met een maximale responsiviteit op de dag van de 
preovulatoire LH piek (Hoofdstuk V). Dit patroon wordt waarschijnlijk niet bei'nvloed door 
EOP's. Dieren die met naltrexon behandeld waren vertoonden weliswaar hogere LH puis 
amplitudes dan controle dieren op 1 dag tijdens de folliculaire fase (Dag 5 in Hoofdstuk IV en 
Dag 4 in Hoofdstuk VII), maar dit verschil was niet langer aanwezig als de data werden 
opgelijnd op het moment van oestrus, derhalve suggererend dat het pulspatroon van LH 
tijdens de folliculaire fase niet wordt bei'nvloed door naltrexon. 
Uit de experimenten van dit proefschrift blijkt dat langdurige aanbindstress leidt tot adaptieve 
veranderingen in de reproductieve as, en dat stress en EOP's tijdens de folliculaire fase, in 
tegenstelling tot de luteal fase, de pulsatiele afgifte van LH niet beinvloeden. Daarentegen 
zijn EOP's tijdens de folliculaire fase betrokken bij de timing van de preovulatoire LH piek en 
het moment van oestrus. 
Dankwoord 129 
Dankwoord 
Tja, het kost wat maar dan heb je ook wat. Nu komt het terugkijken en evalueren. Zo ben ik 
erachter gekomen dat begeleiding in de kwaliteit zit en niet zozeer in de kwantiteit. Ik wil dan 
ook in de allereerste plaats mijn beide promotoren bedanken. Victor en Daan, jullie kritische 
blik heeft mij meerdere malen tot wanhoop gedreven. Maar zonder die blik was het nooit 
zover gekomen. Gelukkig weet ik nu precies wat er voor nodig is om een wetenschapper te 
zijn. Ook wil ik Frans Helmond hierbij bedanken voor de gaatjes die hij nog wist te creeren in 
zijn vaak overvolle agenda. 
Maar wat is het FMD schip zonder bemanning? Een bemanning bestaande uit hard werkende 
analisten, dierverzorgers, "techneuten", secretaresses, docenten/onderzoekers. Allen met 
gouden handjes en harten. Mensen het was een voorrecht om met jullie gewerkt en gelachen 
te hebben. Sorry voor degene die te vaak het slachtoffer waren van Henri's en mijn vrije 
associatie uurtjes. 
Eindelijk kan ik dan ook de dierverzorgers van "De Haar" bedanken. Met Jan Hagens als 
ploegleider, fietsten Ben, Ries, Andre, Peter, Truus en Jack mee en deden veel meer dan van 
hun gevraagd werd. Ook bedankt namens mijn varkens 3249, 3385, 4707, Babs.... 
Collega AIO's en Eline (!), vanaf het AIO weekend kon het echt niet meer stuk. Bedankt voor 
alle gezelligheid en overblijfetentjes op de maandagen dat er gevolleybald moest worden en 
de overige gelegenheden. Henri, ik zal ons "geouwehoer" erg missen. 
Dan de mensen waar ik nauw mee heb samengewerkt. Bas, Nicoline, dr. Bob (Frank van 
Eerdenburg), Corrie, Dick Bongers, Gradus, Wim en Dick van Kleef naast de studenten 
Miriam, de "stress" crew van het jaar 1994, Yvonne, Anite en verder alle vrienden en 
kennissen die mijn wel en wee de afgelopen 6 jaar van dichtbij hebben meegemaakt. Bedankt 
voor jullie geduld en steun. Ik kan jullie nooit beschrij ven hoeveel jullie eigenlijk gedaan 
hebben. 
De "Magnificent Seven" Ingrid, Guido, Marit, Regis, Hinke, Ard en Koen. Zeven namen die 
bij mij heel diep in het hart gegrift zijn. Bedankt, en we spreken elkaar nog. 
Familie is iets ongelofelijk belangrijks in iemands leven. Mam, Christinette, Tanja, Ger, 
Yvonne, Roy, Peter en de afgelopen twee jaar ook Piet, Maria en Pauline. Jullie maken het 
verschil tussen leven en LEVEN. 
Toch is er maar een persoon die mijn leven is. Liefste Lein, jij hebt "de vos getemd". Met de 
liefde, de rust en de kracht die je mij geeft kan ik bergen verzetten en zelfs een proefschrift 
schrijven. Bedankt voor de warmte die je elke dag weer uitstraalt, voor de gemoedelijke 
schouder waar ik op uit kan huilen, en voor alles waar nog geen woorden voor zijn 
uitgevonden. 
Als laatste wil ik hem bedanken die helaas niet meer onder ons is maar waar ik nog elke dag 
van leer: Mijn Vader. Leeve pap, geej het meej aaltied en overaal in gesteund. Dit werk draag 
ik daan ok aan oow op. Bedankt veur aal daat geej meej het gelierd en het laote zeen. Alien 
joamer daat toen ow oege zich vur iewig slote, die vaan meej pas ope gingen. Bedankt en ut 
giet oow good. 
John 
Curriculum Vitae 131 
Curriculum Vitae 
Josephus Antonius Jacobus (John) Dierx werd geboren op 15 juli 1967 te Horst (L). Hij ging 
naar de lagere school "De Weisterbeek" te Horst. Zijn middelbare schooltijd heeft hij 
doorgebracht op het "Boschveldcollege" te Venray. Na de brugklas volgde hij het 
gymnasium. Hij behaalde zijn VWO-diploma in 1985 en startte met de studie Biologie aan de 
Katholieke Universiteit van Nijmegen. Met een tussenstap van 1 jaar naar de studie 
Geneeskunde behaalde hij in 1992 zijn doctoraal diploma in de Biologie. Tijdens zijn studie 
is hij 1 jaar actief geweest als penningmeester van de Nijmeegse Biologenvereninging 
"BeeVee". Van 1 oktober 1992 tot 1 oktober 1996 was hij als AIO verbonden aan de 
vakgroep Fysiologie van Mens en Dier van de Landbouwuniversiteit te Wageningen. Het 
huidige proefschrift is het resultaat van het onderzoek dat hij heeft uitgevoerd. Tijdens deze 
AlO-periode was hij een van de AlO-vertegenwoordigers binnen het vakgroepbestuur. 
Thans volgt hij de 8 maanden durende opleiding "Gezondheidsvoorlichting en Opvoeding" 
aan de Rijksuniversiteit te Utrecht die zal worden afgerond op 29 april 1999. 
